<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1703257079
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1989
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        AMINOPHYLLINE INJ 250MG
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AMINOPHYLLINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        18
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        4.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="HOSPIRA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            HOSPIRA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            HOSPIRA INC
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R03DA05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Aminophylline Injection, USP is a sterile, nonpyrogenic solution of aminophylline in water for injection.</p><p>&nbsp;</p><p>Aminophylline Injection is indicated as an adjunct to inhaled beta-2 selective agonists and systemically administered corticosteroids for the treatment of breathing problems which may occur with:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; asthma</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; emphysema,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bronchitis</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Aminophylline injection</strong> :</p><p>Aminophylline Injection must not be given if you have an allergy to theophylline, ethylenediamine or any of the ingredients listed at the end of this leaflet.</p><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions </strong></p><p><strong><em>WARNINGS</em></strong></p><p><strong>&nbsp;</strong></p><p><strong>Concurrent Illness:</strong></p><p>Theophylline should be used with extreme caution in patients with the following clinical conditions due to the increased risk of exacerbation of the concurrent condition:</p><p>Active peptic ulcer disease</p><p>Seizure disorders</p><p>Cardiac arrhythmias (not including bradyarrhythmias)</p><p><strong>&nbsp;</strong></p><p><strong>Conditions That Reduce Theophylline Clearance:</strong></p><p>There are several readily identifiable causes of reduced theophylline clearance. <strong><em><u>If the infusion rate is not appropriately reduced in the presence of these risk factors, severe and potentially fatal theophylline toxicity can occur.</u></em></strong> Careful consideration must be given to the benefits and risks of theophylline use and the need for more intensive monitoring of serum theophylline concentrations in patients with the following risk factors:</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Age</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neonates (term and premature)</p><p>Children &lt;1 year</p><p>Elderly (&gt;60 years)</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Concurrent Diseases</strong></p><p>Acute pulmonary edema</p><p>Congestive heart failure</p><p>Cor pulmonale</p><p>Fever; &ge;102&deg; for 24 hours or more; or lesser temperature elevations for longer periods</p><p>Hypothyroidism</p><p>Liver disease; cirrhosis, acute hepatitis</p><p>Reduced renal function in infants &lt;3 months of age</p><p>Sepsis with multi-organ failure</p><p>Shock</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cessation of Smoking</strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drug Interactions</strong></p><p>Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See <strong><em>PRECAUTIONS</em></strong>, <strong>Drug Interactions</strong>, <strong>Table 1</strong>.)</p><p><strong>&nbsp;</strong></p><p><strong>When Signs or Symptoms of Theophylline Toxicity Are Present:</strong></p><p><strong><u>Whenever a patient receiving theophylline develops nausea or vomiting, particularly repetitive vomiting, or other signs or symptoms consistent with theophylline toxicity (even if another cause may be suspected), the intravenous infusion should be stopped and a serum theophylline concentration measured immediately.</u></strong></p><p><strong><u>Dosage Increases</u></strong></p><p>&nbsp;</p><p>Increases in the dose of intravenous theophylline should not be made in response to an acute exacerbation of symptoms unless the steady-state serum theophylline concentration is &lt;10&nbsp;mcg/mL.</p><p>&nbsp;</p><p>As the rate of theophylline clearance may be dose-dependent (i.e., steady-state serum concentrations may increase disproportionately to the increase in dose), an increase in dose based upon a sub-therapeutic serum concentration measurement should be conservative. In general, limiting infusion rate increases to about 25% of the previous infusion rate will reduce the risk of unintended excessive increases in serum theophylline concentration (see <strong><em>How to use Aminophylline injection</em></strong>, <strong>TABLE 4</strong>).</p><p>&nbsp;</p><p><strong><em>PRECAUTIONS</em></strong></p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>General</u></strong></p><p>Careful consideration of the various interacting drugs and physiologic conditions that can alter theophylline clearance and require dosage adjustment should occur prior to initiation of theophylline therapy and prior to increases in theophylline dose (see <strong><em>WARNINGS</em></strong>).</p><p><strong>&nbsp;</strong></p><p><strong>Monitoring Serum Theophylline Concentrations:</strong></p><p>Serum theophylline concentration measurements are readily available and should be used to determine whether the dosage is appropriate. Specifically, the serum theophylline concentration should be measured as follows:</p><p>1.&nbsp;&nbsp; Before making a dose increase to determine whether the serum concentration is sub-therapeutic in a patient who continues to be symptomatic.</p><p>2.&nbsp;&nbsp; Whenever signs or symptoms of theophylline toxicity are present.</p><p>3.&nbsp;&nbsp; Whenever there is a new illness, worsening of an existing concurrent illness or a change in the patient&rsquo;s treatment regimen that may alter theophylline clearance (e.g., fever &gt;102&deg;F sustained for &ge;24 hours, hepatitis, or drugs listed in <strong>Table</strong> <strong>1</strong> are added or discontinued).</p><p>&nbsp;</p><p>In patients who have received no theophylline in the previous 24 hours, a serum concentration should be measured 30 minutes after completion of the intravenous loading dose to determine whether the serum concentration is &lt;10 mcg/mL indicating the need for an additional loading dose or &gt;20 mcg/mL indicating the need to delay starting the constant intravenous infusion. Once the infusion is begun, a second measurement should be obtained after one expected half-life (e.g., approximately 4&nbsp;hours in children 1 to 9 years and 8 hours in non-smoking adults; for the expected half-life in additional patient populations). The second measurement should be compared to the first to determine the direction in which the serum concentration has changed. The infusion rate can then be adjusted before steady state is reached in an attempt to prevent an excessive or sub-therapeutic theophylline concentration from being achieved.</p><p>&nbsp;</p><p>If a patient has received theophylline in the previous 24 hours, the serum concentration should be measured before administering an intravenous loading dose to make sure that it is safe to do so. If a loading dose is not indicated (i.e., the serum theophylline concentration is &ge;10 mcg/mL), a second measurement should be obtained as above at the appropriate time after starting the intravenous infusion. If, on the other hand, a loading dose is indicated (See <strong><em>How to use Aminophylline injection</em></strong> for guidance on selection of the appropriate loading dose), a second blood sample should be obtained after the loading dose and a third sample should be obtained one expected half-life after starting the constant infusion to determine the direction in which the serum concentration has changed.</p><p>&nbsp;</p><p>Once the above procedures related to initiation of intravenous theophylline infusion have been completed, subsequent serum samples for determination of theophylline concentration should be obtained at 24-hour intervals for the duration of the infusion. The theophylline infusion rate should be increased or decreased as appropriate based on the serum theophylline levels.</p><p>&nbsp;</p><p>When signs or symptoms of theophylline toxicity are present, the intravenous infusion should be stopped and a serum sample for theophylline concentration should be obtained as soon as possible, analyzed immediately, and the result reported to the clinician without delay. In patients in whom decreased serum protein binding is suspected (e.g., cirrhosis, women during the third trimester of pregnancy), the concentration of unbound theophylline should be measured and the dosage adjusted to achieve an unbound concentration of 6-12 mcg/mL.</p><p>&nbsp;</p><p>Saliva concentrations of theophylline cannot be used reliably to adjust dosage without special techniques.</p><p><br /><strong>Effects on Laboratory Tests:</strong></p><p>As a result of its pharmacological effects, theophylline at serum concentrations within the 10&nbsp;‑&nbsp;20&nbsp;mcg/mL range modestly increases plasma glucose (from a mean of 88 mg% to 98 mg%), uric acid (from a mean of 4 mg/dl to 6 mg/dl), free fatty acids (from a mean of 451 &micro;Eq/L to 800&nbsp;&micro;Eq/L), total cholesterol (from a mean of 140 vs 160 mg/dl), HDL (from a mean of 36 to 50&nbsp;mg/dl), HDL/LDL ratio (from a mean of 0.5 to 0.7), and urinary free cortisol excretion (from a mean of 44 to 63 mcg/24 hr). Theophylline at serum concentrations within the 10 - 20 mcg/mL range may also transiently decrease serum concentrations of triiodothyronine (144 before, 131 after one week and 142 ng/dl after 4 weeks of theophylline). The clinical importance of these changes should be weighed against the potential therapeutic benefit of theophylline in individual patients.</p><p>&nbsp;</p><p><strong>Other medicines and Aminophylline injection</strong>:</p><p>Theophylline interacts with a wide variety of drugs. The interaction may be pharmacodynamic, i.e., alterations in the therapeutic response to theophylline or another drug or occurrence of adverse effects without a change in serum theophylline concentration. More frequently, however, the interaction is pharmacokinetic, i.e., the rate of theophylline clearance is altered by another drug resulting in increased or decreased serum theophylline concentrations. Theophylline only rarely alters the pharmacokinetics of other drugs.</p><p>&nbsp;</p><p>The drugs listed in <strong>Table 1</strong> have the potential to produce clinically significant pharmacodynamic or pharmacokinetic interactions with theophylline. The information in the &ldquo;Effect&rdquo; column of <strong>Table 1</strong> assumes that the interacting drug is being added to a steady-state theophylline regimen. If theophylline is being initiated in a patient who is already taking a drug that inhibits theophylline clearance (e.g., cimetidine, erythromycin), the dose of theophylline required to achieve a therapeutic serum theophylline concentration will be smaller. Conversely, if theophylline is being initiated in a patient who is already taking a drug that enhances theophylline clearance (e.g., rifampin), the dose of theophylline required to achieve a therapeutic serum theophylline concentration will be larger. Discontinuation of a concomitant drug that increases theophylline clearance will result in accumulation of theophylline to potentially toxic levels, unless the theophylline dose is appropriately reduced. Discontinuation of a concomitant drug that inhibits theophylline clearance will result in decreased serum theophylline concentrations, unless the theophylline dose is appropriately increased.</p><p>&nbsp;</p><p>The drugs listed in <strong>Table 2</strong> have either been documented not to interact with theophylline or do not produce a clinically significant interaction (i.e., &lt;15% change in theophylline clearance).</p><p>&nbsp;</p><p>The listing of drugs in <strong>Tables 1 and 2</strong> are current as of September 1, 1995. New interactions are continuously being reported for theophylline, especially with new chemical entities. <strong><u>The clinician should not assume that a drug does not interact with theophylline if it is not listed in Table 1.</u></strong> Before addition of a newly available drug in a patient receiving theophylline, the package insert of the new drug and/or the medical literature should be consulted to determine if an interaction between the new drug and theophylline has been reported.</p><p><strong>Table 1.&nbsp;&nbsp; Clinically Significant Drug Interactions With Theophylline*</strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:bottom"><p><strong>Drug</strong></p></td><td style="vertical-align:bottom"><p><strong>Type Of Interaction</strong></p></td><td style="vertical-align:bottom"><p><strong>Effect**</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Adenosine</p></td><td style="vertical-align:top"><p>Theophylline blocks adenosine</p><p>receptors.</p></td><td style="vertical-align:top"><p>Higher doses of adenosine may be required to achieve desired effect.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Alcohol</p></td><td style="vertical-align:top"><p>A single large dose of alcohol</p><p>(3 mL/kg of whiskey) decreases</p><p>theophylline clearance for up to 24 hours.</p></td><td style="vertical-align:top"><p>30% increase</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Allopurinol</p></td><td style="vertical-align:top"><p>Decreases theophylline clearance at allopurinol doses &ge;600 mg/day.</p></td><td style="vertical-align:top"><p>25% increase</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Aminoglutethimide</p></td><td style="vertical-align:top"><p>Increases theophylline clearance by</p><p>induction of microsomal enzyme activity.</p></td><td style="vertical-align:top"><p>25% decrease</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Carbamazepine</p></td><td style="vertical-align:top"><p>Similar to aminoglutethimide.</p></td><td style="vertical-align:top"><p>30% decrease</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cimetidine</p></td><td style="vertical-align:top"><p>Decreases theophylline clearance by inhibiting cytochrome P450 1A2.</p></td><td style="vertical-align:top"><p>70% increase</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ciprofloxacin</p></td><td style="vertical-align:top"><p>Similar to cimetidine.&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>40% increase</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Clarithromycin</p></td><td style="vertical-align:top"><p>Similar to erythromycin.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>25% increase</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Diazepam</p></td><td style="vertical-align:top"><p>Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors.</p></td><td style="vertical-align:top"><p>Larger diazepam doses may be</p><p>required to produce desired level of sedation. Discontinuation of theophylline without reduction of diazepam dose may result in respiratory depression.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Disulfiram</p></td><td style="vertical-align:top"><p>Decreases theophylline clearance by inhibiting hydroxylation and demethylation.</p></td><td style="vertical-align:top"><p>50% increase</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Enoxacin</p></td><td style="vertical-align:top"><p>Similar to cimetidine.&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>300% increase</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ephedrine</p></td><td style="vertical-align:top"><p>Synergistic CNS effects.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>Increased frequency of nausea,</p><p>nervousness, and insomnia.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Erythromycin</p></td><td style="vertical-align:top"><p>Erythromycin metabolite decreases theophylline clearance by inhibiting</p><p>cytochrome P450 3A3.</p></td><td style="vertical-align:top"><p>35% increase. Erythromycin</p><p>steady-state serum concentrations decrease by a similar amount.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Estrogen</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Estrogen containing oral contraceptives decrease theophylline clearance in a dose-dependent fashion.</p><p>The effect of progesterone on theophylline clearance is unknown.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>30% increase</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Flurazepam</p></td><td style="vertical-align:top"><p>Similar to diazepam.</p></td><td style="vertical-align:top"><p>Similar to diazepam.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table 1.&nbsp;&nbsp; Clinically Significant Drug Interactions With Theophylline* (continued)</strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:bottom"><p><strong>Drug</strong></p></td><td style="vertical-align:bottom"><p><strong>Type Of Interaction</strong></p></td><td style="vertical-align:bottom"><p><strong>Effect**</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Fluvoxamine</p></td><td style="vertical-align:top"><p>Similar to cimetidine.</p></td><td style="vertical-align:top"><p>Similar to cimetidine.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Halothane</p></td><td style="vertical-align:top"><p>Halothane sensitizes the myocardium</p><p>to catecholamines, theophylline</p><p>increases release of endogenous</p><p>catecholamines.</p></td><td style="vertical-align:top"><p>Increased risk of ventricular</p><p>arrhythmias.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Interferon, human</p><p>recombinant alpha-A</p></td><td style="vertical-align:top"><p>Decreases theophylline clearance.</p></td><td style="vertical-align:top"><p>100% increase</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Isoproterenol (I.V.)</p></td><td style="vertical-align:top"><p>Increases theophylline clearance.</p></td><td style="vertical-align:top"><p>20% decrease</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ketamine</p></td><td style="vertical-align:top"><p>Pharmacologic</p></td><td style="vertical-align:top"><p>May lower theophylline</p><p>seizure threshold.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Lithium</p></td><td style="vertical-align:top"><p>Theophylline increases renal lithium clearance.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>Lithium dose required to achieve a therapeutic serum concentration increased an average of 60%.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Lorazepam</p></td><td style="vertical-align:top"><p>Similar to diazepam.</p></td><td style="vertical-align:top"><p>Similar to diazepam.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Methotrexate (MTX)</p></td><td style="vertical-align:top"><p>Decreases theophylline clearance.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>20% increase after low dose MTX, higher dose MTX may have a greater effect.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Mexiletine</p></td><td style="vertical-align:top"><p>Similar to disulfiram.</p></td><td style="vertical-align:top"><p>80% increase</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Midazolam</p></td><td style="vertical-align:top"><p>Similar to diazepam.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>Similar to diazepam.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Moricizine</p></td><td style="vertical-align:top"><p>Increases theophylline clearance.</p></td><td style="vertical-align:top"><p>25% decrease</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pancuronium</p></td><td style="vertical-align:top"><p>Theophylline may antagonize</p><p>nondepolarizing neuromuscular blocking effects; possibly due to phosphodiesterase inhibition.</p></td><td style="vertical-align:top"><p>Larger dose of pancuronium may be required to achieve neuromuscular blockade.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pentoxifylline</p></td><td style="vertical-align:top"><p>Decreases theophylline clearance.</p></td><td style="vertical-align:top"><p>30% increase</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Phenobarbital (PB)</p></td><td style="vertical-align:top"><p>Similar to aminoglutethimide.</p></td><td style="vertical-align:top"><p>25% decrease after two weeks of concurrent Phenobarbital.</p></td></tr><tr><td style="vertical-align:top"><p>Phenytoin</p></td><td style="vertical-align:top"><p>Phenytoin increases theophylline</p><p>clearance by increasing microsomal</p><p>enzyme activity. Theophylline decreases</p><p>phenytoin absorption.</p></td><td style="vertical-align:top"><p>Serum theophylline and phenytoin concentrations decrease about 40%.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Propafenone</p></td><td style="vertical-align:top"><p>Decreases theophylline clearance and</p><p>pharmacologic interaction.</p></td><td style="vertical-align:top"><p>40% increase. Beta-2 blocking</p><p>effect may decrease efficacy of theophylline.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table 1.&nbsp;&nbsp; Clinically Significant Drug Interactions With Theophylline* (continued)</strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Drug</strong></p></td><td style="vertical-align:top"><p><strong>Type Of Interaction</strong></p></td><td style="vertical-align:top"><p><strong>Effect**</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Propranolol</p></td><td style="vertical-align:top"><p>Similar to cimetidine and pharmacologic interaction.</p></td><td style="vertical-align:top"><p>100% increase. Beta-2 blocking</p><p>effect may decrease efficacy of theophylline.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rifampin</p></td><td style="vertical-align:top"><p>Increases theophylline clearance by</p><p>increasing cytochrome P450 1A2 and 3A3 activity.</p></td><td style="vertical-align:top"><p>20 - 40% decrease</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Sulfinpyrazone</p></td><td style="vertical-align:top"><p>Increases theophylline clearance by</p><p>increasing demethylation and hydroxylation. Decreases renal clearance of theophylline.</p></td><td style="vertical-align:top"><p>20% decrease</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Tacrine</p></td><td style="vertical-align:top"><p>Similar to cimetidine, also increases renal clearance of theophylline.</p></td><td style="vertical-align:top"><p>90% increase</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Thiabendazole</p></td><td style="vertical-align:top"><p>Decreases theophylline clearance.</p></td><td style="vertical-align:top"><p>190% increase</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ticlopidine</p></td><td style="vertical-align:top"><p>Decreases theophylline clearance.</p></td><td style="vertical-align:top"><p>60% increase</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Troleandomycin</p></td><td style="vertical-align:top"><p>Similar to erythromycin.</p></td><td style="vertical-align:top"><p>33 - 100% increase depending on troleandomycin dose.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Verapamil</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Similar to disulfiram.</p></td><td style="vertical-align:top"><p>20% increase</p></td></tr></tbody></table><p><strong>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Refer to<strong> <em>PRECAUTIONS</em>, Drug Interactions </strong>for further information regarding table.</p><p><strong>**</strong>&nbsp;&nbsp; Average effect on steady-state theophylline concentration or other clinical effect for pharmacologic interactions. Individual patients may experience larger changes in serum theophylline concentration than the value listed.</p><p>&nbsp;</p><p><strong>Table 2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drugs That Have Been Documented Not to Interact With Theophylline or</strong></p><p><strong>Drugs That Produce No Clinically Significant Interaction With Theophylline*</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>albuterol,</p><p>&nbsp;&nbsp; systemic and inhaled</p><p>amoxicillin</p><p>ampicillin,</p><p>&nbsp;&nbsp; with or without sulbactam</p><p>atenolol</p><p>azithromycin</p><p>caffeine,</p><p>&nbsp;&nbsp; dietary ingestion</p><p>cefaclor</p><p>co-trimoxazole</p><p>&nbsp;&nbsp; (trimethoprim and sulfamethoxazole)</p><p>diltiazem</p><p>dirithromycin</p><p>enflurane</p><p>famotidine</p><p>felodipine</p><p>finasteride</p><p>hydrocortisone</p><p>isoflurane</p><p>isoniazid</p><p>isradipine</p><p>influenza vaccine</p><p>ketoconazole</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>lomefloxacin</p><p>mebendazole</p><p>medroxyprogesterone</p><p>methylprednisolone</p><p>metronidazole</p><p>metoprolol</p><p>nadolol</p><p>nifedipine</p><p>nizatidine</p><p>norfloxacin</p><p>ofloxacin</p><p>omeprazole</p><p>prednisone, prednisolone</p><p>ranitidine</p><p>rifabutin</p><p>roxithromycin</p><p>sorbitol</p><p>&nbsp; (purgative doses do not inhibit</p><p>&nbsp; theophylline absorption)</p><p>sucralfate</p><p>terbutaline, systemic</p><p>terfenadine</p><p>tetracycline</p><p>tocainide</p></td></tr></tbody></table><p><strong>* </strong>Refer to<strong> <em>PRECAUTIONS</em>, Drug Interactions </strong>for information regarding table.</p><p><strong>&nbsp;</strong></p><p><strong>The Effect of Other Drugs on Theophylline Serum Concentration Measurements:</strong></p><p>Most serum theophylline assays in clinical use are immunoassays which are specific for theophylline. Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays. Some drugs (e.g., cefazolin, cephalothin), however, may interfere with certain HPLC techniques. Caffeine and xanthine metabolites in neonates or patients with renal dysfunction may cause the reading from some dry reagent office methods to be higher than the actual serum theophylline concentration.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p><strong>Pediatric Use:</strong></p><p>Theophylline is safe and effective for the approved indications in pediatric patients (see <strong><em>INDICATIONS AND USAGE</em></strong>). The constant infusion rate of intravenous theophylline must be selected with caution in pediatric patients since the rate of theophylline clearance is highly variable across the age range of neonates to adolescents (see <strong><em>CLINICAL PHARMACOLOGY</em></strong>, <strong><em>WARNINGS</em></strong>, and <strong><em>How to use Aminophylline injection</em></strong>, <strong>Table 3</strong>). Due to the immaturity of theophylline metabolic pathways in pediatric patients under the age of one year, particular attention to dosage selection and frequent monitoring of serum theophylline concentrations are required when theophylline is prescribed to pediatric patients in this age group.</p><p><strong>&nbsp;</strong></p><p><strong>Geriatric Use:</strong></p><p>Elderly patients are at significantly greater risk of experiencing serious toxicity from theophylline than younger patients due to pharmacokinetic and pharmacodynamic changes associated with aging. Theophylline clearance is reduced in patients greater than 60 years of age, resulting in increased serum theophylline concentrations in response to a given theophylline infusion rate. Protein binding may be decreased in the elderly resulting in a larger proportion of the total serum theophylline concentration in the pharmacologically active unbound form. Elderly patients also appear to be more sensitive to the toxic effects of theophylline after chronic overdosage than younger patients. For these reasons, the maximum infusion rate of theophylline in patients greater than 60 years of age ordinarily should not exceed 17 mg/hr (21 mg/hr as aminophylline) unless the patient continues to be symptomatic and the peak steady state serum theophylline concentration is &lt;10 mcg/mL (see <strong><em>How to use Aminophylline injection</em></strong>). Theophylline infusion rates greater than 17 mg/hr (21 mg/hr as aminophylline) should be prescribed with caution in elderly patients.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy: </strong></p><p>There are no adequate and well controlled studies in pregnant women. Additionally, there are no teratogenicity studies in nonrodents (e.g., rabbits). Theophylline was not shown to be teratogenic in CD-1 mice at oral doses up to 400 mg/kg, approximately 2.0 times the human dose on a mg/m<sup>2</sup> basis or in CD-1 rats at oral doses up to 260 mg/kg, approximately 3.0 times the recommended human dose on a mg/m<sup>2</sup> basis.&nbsp; At a dose of 220 mg/kg, embryotoxicity was observed in rats in the absence of maternal toxicity.</p><p><strong>&nbsp;</strong></p><p><strong>Nursing Mothers:</strong></p><p>Theophylline is excreted into breast milk and may cause irritability or other signs of mild toxicity in nursing human infants. The concentration of theophylline in breast milk is about equivalent to the maternal serum concentration. An infant ingesting a liter of breast milk containing 10&nbsp;‑&nbsp;20&nbsp;mcg/mL of theophylline per day is likely to receive 10 - 20 mg of theophylline per day. Serious adverse effects in the infant are unlikely unless the mother has toxic serum theophylline concentrations.</p><p><strong>&nbsp;</strong></p><p><strong>Carcinogenesis, Mutagenesis, and Impairment of Fertility:</strong></p><p>Long term carcinogenicity studies have been carried out in mice (oral doses 30 - 150 mg/kg) and rats (oral doses 5 - 75 mg/kg). Results are pending.</p><p>Theophylline has been studied in Ames salmonella, <em>in vivo</em> and <em>in vitro</em> cytogenetics, micronucleus and Chinese hamster ovary test systems and has not been shown to be genotoxic.</p><p>In a 14 week continuous breeding study, theophylline, administered to mating pairs of B6C3F<sub>1</sub> mice at oral doses of 120, 270 and 500 mg/kg (approximately 1.0 - 3.0 times the human dose on a mg/m<sup>2</sup> basis) impaired fertility, as evidenced by decreases in the number of live pups per litter, decreases in the mean number of litters per fertile pair, and increases in the gestation period at the high dose as well as decreases in the proportion of pups born alive at the mid and high dose. In 13&nbsp;week toxicity studies, theophylline was administered to F344 rats and B6C3F<sub>1</sub> mice at oral doses of 40 - 300 mg/kg (approximately 2 times the human dose on a mg/m<sup>2</sup> basis). At the high dose, systemic toxicity was observed in both species including decreases in testicular weight.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>&nbsp;</p><p>Not applicable.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>General Considerations:</strong></p><p>The steady-state serum theophylline concentration is a function of the infusion rate and the rate of theophylline clearance in the individual patient. Because of marked individual differences in the rate of theophylline clearance, the dose required to achieve a serum theophylline concentration in the<br />10-20 mcg/mL range varies fourfold among otherwise similar patients in the absence of factors known to alter theophylline clearance. For a given population there is no single theophylline dose that will provide both safe and effective serum concentrations for all patients. Administration of the median theophylline dose required to achieve a therapeutic serum theophylline concentration in a given population may result in either sub-therapeutic or potentially toxic serum theophylline concentrations in individual patients. <strong><u>The dose of theophylline must be individualized on the basis of serum theophylline concentration measurements in order to achieve a dose that will provide maximum potential benefit with minimal risk of adverse effects.</u></strong></p><p>&nbsp;</p><p>When theophylline is used as an acute bronchodilator, the goal of obtaining a therapeutic serum concentration is best accomplished with an intravenous loading dose. Because of rapid distribution into body fluids, the serum concentration (C) obtained from an initial loading dose (LD) is related primarily to the volume of distribution (V), the apparent space into which the drug diffuses:</p><p>C = LD/V</p><p>&nbsp;</p><p>If a mean volume of distribution of about 0.5 L/kg is assumed (actual range is 0.3 to 0.7 L/kg), each mg/kg (ideal body weight) of theophylline administered as a loading dose over 30 minutes results in an average 2 mcg/mL increase in serum theophylline concentration. Therefore, in a patient who has received no theophylline in the previous 24 hours, a loading dose of intravenous theophylline of 4.6mg/kg (5.7 mg/kg as aminophylline), calculated on the basis of ideal body weight and administered over 30 minutes, on average, will produce a maximum post-distribution serum concentration of 10 mcg/mL with a range of 6-16 mcg/mL. When a loading dose becomes necessary in the patient who has already received theophylline, estimation of the serum concentration based upon the history is unreliable, and an immediate serum level determination is indicated. The loading dose can then be determined as follows:</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; D = (Desired C - Measured C) (V)</p><p>where D is the loading dose, C is the serum theophylline concentration, and V is the volume of distribution. The mean volume of distribution can be assumed to be 0.5 L/kg and the desired serum concentration should be conservative (e.g., 10 mcg/mL) to allow for the variability in the volume of distribution. <strong><u>A loading dose should not be given before obtaining a serum theophylline concentration if the patient has received any theophylline in the previous 24 hours.</u></strong></p><p>&nbsp;</p><p>A serum concentration obtained 30 minutes after an intravenous loading dose, when distribution is complete, can be used to assess the need for and size of subsequent loading doses, if clinically indicated, and for guidance of continuing therapy. Once a serum concentration of 10 to 15 mcg/mL has been achieved with the use of a loading dose(s), a constant intravenous infusion is started. The rate of administration is based upon mean pharmacokinetic parameters for the population and calculated to achieve a target serum concentration of 10 mcg/mL (see <strong>Table 3</strong>). For example, in non-smoking adults, initiation of a constant intravenous theophylline infusion of 0.4&nbsp;mg/kg/hr (0.5 mg/kg/hr as aminophylline) at the completion of the loading dose, on average, will result in a steady-state concentration of 10 mcg/mL with a range of 7-26 mcg/mL. The mean and range of steady-state serum concentrations are similar when the average child (age 1 to 9 years) is given a loading dose of 4.6 mg/kg theophylline (5.7 mg/kg as aminophylline) followed by a constant intravenous infusion of 0.8 mg/kg/hr (1.0 mg/kg/hr as aminophylline). Since there is large interpatient variability in theophylline clearance, serum concentrations will rise or fall when the patient&rsquo;s clearance is significantly different from the mean population value used to calculate the initial infusion rate. Therefore, a second serum concentration should be obtained one expected half-life after starting the constant infusion (e.g., approximately 4 hours for children age 1 to 9 and 8&nbsp;hours for nonsmoking adults; for the expected half-life in additional patient populations) to determine if the concentration is accumulating or declining from the post loading dose level. If the level is declining as a result of a higher than average clearance, an additional loading dose can be administered and/or the infusion rate increased. In contrast, if the second sample demonstrates a higher level, accumulation of the drug can be assumed, and the infusion rate should be decreased before the concentration exceeds 20 mcg/mL. An additional sample is obtained 12 to 24 hours later to determine if further adjustments are required and then at 24-hour intervals to adjust for changes, if they occur. This empiric method, based upon mean pharmacokinetic parameters, will prevent large fluctuations in serum concentration during the most critical period of the patient&rsquo;s course.</p><p>&nbsp;</p><p>In patients with cor pulmonale, cardiac decompensation, or liver dysfunction, or in those taking drugs that markedly reduce theophylline clearance (e.g., cimetidine), the initial theophylline infusion rate should not exceed 17 mg/hr (21 mg/hr as aminophylline) unless serum concentrations can be monitored at 24-hour intervals. In these patients, 5 days may be required before steady-state is reached.</p><p>&nbsp;</p><p>Theophylline distributes poorly into body fat, therefore, mg/kg dose should be calculated on the basis of ideal body weight.</p><p><strong>&nbsp;</strong></p><p><strong>Table 3</strong> contains initial theophylline infusion rates following an appropriate loading dose recommended for patients in various age groups and clinical circumstances. <strong>Table 4</strong> contains recommendations for final theophylline dosage adjustment based upon serum theophylline concentrations. <strong><u>Application of these general dosing recommendations to individual patients must take into account the unique clinical characteristics of each patient. In general, these recommendations should serve as the upper limit for dosage adjustments in order to decrease the risk of potentially serious adverse events associated with unexpected large increases in serum theophylline concentration.</u></strong></p><p>&nbsp;</p><p><strong>Table 3.&nbsp; &nbsp;Initial Theophylline Infusion Rates Following an Appropriate Loading Dose.</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Patient population</strong></p></td><td style="vertical-align:top"><p><strong>Age</strong></p></td><td style="vertical-align:top"><p><strong>Theophylline infusion rate (mg/kg/hr)*&dagger;&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Neonates</p></td><td style="vertical-align:top"><p>Postnatal age up to 24 days</p><p>Postnatal age beyond 24 days</p></td><td style="vertical-align:top"><p>1 mg/kg q12h/&Dagger;</p><p>1.5 mg/kg q12h/&Dagger;</p></td></tr><tr><td style="vertical-align:top"><p>Infants</p></td><td style="vertical-align:top"><p>6-52 weeks old</p></td><td style="vertical-align:top"><p>mg/kg/hr= (0.008)(age in weeks) + 0.21</p></td></tr><tr><td style="vertical-align:top"><p>Young children</p></td><td style="vertical-align:top"><p>1-9 years</p></td><td style="vertical-align:top"><p>0.8</p></td></tr><tr><td style="vertical-align:top"><p>Older children</p></td><td style="vertical-align:top"><p>9-12 years</p></td><td style="vertical-align:top"><p>0.7</p></td></tr><tr><td style="vertical-align:top"><p>Adolescents</p><p>&nbsp; (cigarette or marijuana</p><p>&nbsp; smokers)</p></td><td style="vertical-align:top"><p>12-16 years</p></td><td style="vertical-align:top"><p>0.7</p></td></tr><tr><td style="vertical-align:top"><p>Adolescents (nonsmokers)</p></td><td style="vertical-align:top"><p>12-16 years</p></td><td style="vertical-align:top"><p>0.5 &sect;</p></td></tr><tr><td style="vertical-align:top"><p>Adults</p><p>&nbsp; (otherwise healthy</p><p>&nbsp; nonsmokers)</p></td><td style="vertical-align:top"><p>16-60 years</p></td><td style="vertical-align:top"><p>0.4 &sect;</p></td></tr><tr><td style="vertical-align:top"><p>Elderly</p></td><td style="vertical-align:top"><p>&gt;60 years</p></td><td style="vertical-align:top"><p>0.3 ı</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac decompensation,</p><p>&nbsp; cor pulmonale, liver</p><p>&nbsp; dysfunction, sepsis with</p><p>&nbsp; multiorgan failure,</p><p>&nbsp; or shock</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>0.2 ı</p></td></tr></tbody></table><p>*&nbsp; To achieve a target concentration of 10 mcg/mL Aminophylline=theophylline/0.8. Use ideal body weight for obese patients.</p><p>&dagger;&nbsp; Lower initial dosage may be required for patients receiving other drugs that decrease theophylline clearance (e.g., cimetidine).</p><p>&Dagger;&nbsp; To achieve a target concentration of 7.5 mcg/mL for neonatal apnea.</p><p>&sect;&nbsp; Not to exceed 900 mg/day, unless serum levels indicate the need for a larger dose.</p><p>&nbsp;ı&nbsp; Not to exceed 400 mg/day, unless serum levels indicate the need for a larger dose.</p><p>&nbsp;</p><p><strong>Table 4.&nbsp;&nbsp; Final Dosage Adjustment Guided by Serum Theophylline Concentration</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:684px"><tbody><tr><td style="vertical-align:top"><p><strong>Peak Serum Concentration</strong></p></td><td style="vertical-align:top"><p><strong>Dosage Adjustment</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&lt;9.9 mcg/mL</p></td><td style="vertical-align:bottom"><p>If symptoms are not controlled and current dosage is tolerated, increase infusion rate about 25%. Recheck serum concentration after 12 hours in children and 24 hours in adults for further dosage adjustment.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>10 to 14.9 mcg/mL</p></td><td style="vertical-align:bottom"><p>If symptoms are controlled and current dosage is tolerated, maintain infusion rate and recheck serum concentration at 24 hour intervals.&para; If symptoms are not controlled and current dosage is tolerated consider adding additional medication(s) to treatment regimen.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>15-19.9 mcg/mL</p></td><td style="vertical-align:bottom"><p>Consider 10% decrease in infusion rate to provide greater margin of safety even if current dosage is tolerated.&para;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>20-24.9 mcg/mL</p></td><td style="vertical-align:bottom"><p>Decrease infusion rate by 25% even if no adverse effects are present. Recheck serum concentration after 12 hours in children and 24 hours in adults to guide further dosage adjustment.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>25-30 mcg/mL</p></td><td style="vertical-align:bottom"><p>Stop infusion for 12 hours in children and 24 hours in adults and decrease subsequent infusion rate at least 25% even if no adverse effects are present. Recheck serum concentration after 12 hours in children and 24 hours in adults to guide further dosage adjustment. If symptomatic, stop infusion and consider whether overdose treatment is indicated (see recommendations for chronic overdosage).</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;30 mcg/mL</p></td><td style="vertical-align:bottom"><p>Stop the infusion and treat overdose as indicated (see recommendations for chronic overdosage). If theophylline is subsequently resumed, decrease infusion rate by at least 50% and recheck serum concentration after 12 hours in children and 24 hours in adults to guide further dosage adjustment.</p></td></tr></tbody></table><p>&para;&nbsp;&nbsp;&nbsp; Dose reduction and/or serum theophylline concentration measurement is indicated whenever adverse effects are present, physiologic abnormalities that can reduce theophylline clearance occur (e.g., sustained fever), or a drug that interacts with theophylline is added or discontinued (see <strong><em>WARNINGS</em></strong>).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Adverse reactions associated with theophylline are generally mild when peak serum theophylline concentrations are &lt;20 mcg/mL and mainly consist of transient caffeine-like adverse effects such as nausea, vomiting, headache, and insomnia. When peak serum theophylline concentrations exceed<br />20 mcg/mL, however, theophylline produces a wide range of adverse reactions including persistent vomiting, cardiac arrhythmias, and intractable seizures which can be lethal (see <strong><em>OVERDOSAGE</em></strong>).</p><p>Other adverse reactions that have been reported at serum theophylline concentrations &lt;20&nbsp;mcg/mL include diarrhea, irritability, restlessness, fine skeletal muscle tremors, and transient diuresis. In patients with hypoxia secondary to COPD, multifocal atrial tachycardia and flutter have been reported at serum theophylline concentrations &ge;15 mcg/mL. There have been a few isolated reports of seizures at serum theophylline concentrations &lt;20 mcg/mL in patients with an underlying neurological disease or in elderly patients.</p><p>&nbsp;</p><p>The occurrence of seizures in elderly patients with serum theophylline concentrations<br />&lt;20 mcg/mL may be secondary to decreased protein binding resulting in a larger proportion of the total serum theophylline concentration in the pharmacologically active unbound form. The clinical characteristics of the seizures reported in patients with serum theophylline concentrations &lt;20 mcg/mL have generally been milder than seizures associated with excessive serum theophylline concentrations resulting from an overdose (i.e., they have generally been transient, often stopped without anticonvulsant therapy, and did not result in neurological residua).</p><p>&nbsp;</p><p>Products containing aminophylline may rarely produce severe allergic reactions of the skin, including exfoliative dermatitis, after systemic administration in a patient who has been previously sensitized by topical application of a substance containing ethylenediamine. In such patients skin patch tests are positive for ethylenediamine, a component of aminophylline, and negative for theophylline. Pharmacists and other individuals who experience repeated skin exposure while physically handling aminophylline may develop a contact dermatitis due to the ethylenediamine component.</p><p>&nbsp;</p><p><strong>Table 5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Manifestations of Theophylline Toxicity*</strong></p><p><strong>Percentage of Patients Reported With Sign or Symptom</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:684px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Acute Overdose</strong></p><p><strong>(Large Single Ingestion)</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Chronic Overdosage</strong></p><p><strong>(Multiple Excessive Doses)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Sign/Symptom</strong></p></td><td style="vertical-align:top"><p><strong>Study 1</strong></p><p><strong>(n=157)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Study 2</strong></p><p><strong>(n=14)</strong></p></td><td style="vertical-align:top"><p><strong>Study 1</strong></p><p><strong>(n=92)</strong></p></td><td style="vertical-align:top"><p><strong>Study 2</strong></p><p><strong>(n=102)</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Asymptomatic</u></p></td><td style="vertical-align:top"><p>NR**</p></td><td colspan="2" style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>NR**</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p><u>Gastrointestinal</u></p><p>&nbsp;&nbsp; Vomiting</p><p>&nbsp;&nbsp; Abdominal pain</p><p>&nbsp;&nbsp; Diarrhea</p><p>&nbsp;&nbsp; Hematemesis</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>73</p><p>NR**</p><p>NR**</p><p>NR**</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>93</p><p>21</p><p>0</p><p>0</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>30</p><p>NR**</p><p>NR**</p><p>NR**</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>61</p><p>12</p><p>14</p><p>2</p></td></tr><tr><td style="vertical-align:top"><p><u>Metabolic/Other</u></p><p>&nbsp;&nbsp; Hypokalemia</p><p>&nbsp;&nbsp; Hyperglycemia</p><p>&nbsp;&nbsp; Acid/base disturbance</p><p>&nbsp;&nbsp; Rhabdomyolysis</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>85</p><p>98</p><p>34</p><p>NR**</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>79</p><p>NR**</p><p>21</p><p>7</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>44</p><p>18</p><p>9</p><p>NR**</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>43</p><p>NR**</p><p>5</p><p>0</p></td></tr><tr><td style="vertical-align:top"><p><u>Cardiovascular</u></p><p>&nbsp;&nbsp; Sinus tachycardia</p><p>&nbsp;&nbsp; Other supraventricular</p><p>&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tachycardias</p><p>&nbsp;&nbsp; Ventricular premature beats</p><p>&nbsp;&nbsp; Atrial fibrillation or flutter</p><p>&nbsp;&nbsp; Multifocal atrial tachycardia</p><p>&nbsp;&nbsp; Ventricular arrhythmias with</p><p>&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hemodynamic instability</p><p>&nbsp;&nbsp; Hypotension/shock</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>100</p><p>2</p><p>&nbsp;</p><p>3</p><p>1</p><p>0</p><p>7</p><p>&nbsp;</p><p>NR**</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>86</p><p>21</p><p>&nbsp;</p><p>21</p><p>NR**</p><p>NR**</p><p>14</p><p>&nbsp;</p><p>21</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>100</p><p>12</p><p>&nbsp;</p><p>10</p><p>12</p><p>2</p><p>40</p><p>&nbsp;</p><p>NR**</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>62</p><p>14</p><p>&nbsp;</p><p>19</p><p>NR**</p><p>NR**</p><p>0</p><p>&nbsp;</p><p>8</p></td></tr><tr><td style="vertical-align:top"><p><u>Neurologic</u></p><p>&nbsp;&nbsp; Nervousness</p><p>&nbsp;&nbsp; Tremors</p><p>&nbsp;&nbsp; Disorientation</p><p>&nbsp;&nbsp; Seizures</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>NR**</p><p>38</p><p>NR**</p><p>5</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>64</p><p>29</p><p>7</p><p>14</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>NR**</p><p>16</p><p>NR**</p><p>14</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>21</p><p>14</p><p>11</p><p>5</p></td></tr><tr><td style="vertical-align:top"><p><u>Death</u></p></td><td style="vertical-align:top"><p>3</p></td><td colspan="2" style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; These data are derived from two studies in patients with serum theophylline concentrations<br />&gt;30 mcg/mL. In the first study (Study #1 &ndash; Shanon, Ann Intern Med 1993;119:1161-67), data were prospectively collected from 249 consecutive cases of theophylline toxicity referred to a regional poison center for consultation. In the second study (Study #2 &ndash; Sessler, Am J Med 1990; 88:567-76), data were retrospectively collected from 116 cases with serum theophylline concentrations &gt;30 mcg/mL among 6000 blood samples obtained for measurement of serum theophylline concentrations in three emergency departments. Differences in the incidence of manifestations of theophylline toxicity between the two studies may reflect sample selection as a result of study design (e.g., in Study #1, 48% of the patients had acute intoxications versus only 10% in Study #2) and different methods of reporting results.</p><p>**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NR = Not reported in a comparable manner</p><p>&nbsp;</p><p><strong>Reporting of side effects:</strong><br />If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p><strong>&nbsp;</strong></p><p><strong>To report side effects: </strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp; Call center: 19999</p><p>&middot;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Shelf life: 18 months</p><p>store below 25&deg;C.</p><p>Protect from light. Store in carton until time of use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>25 mg/mL Aminophylline, Dihydrate</p><p>(Equivalent to 19.7 mg/mL of Anhydrous Theophylline)</p><p>Ethylenediamine, Nitrogen, Water for Injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Aminophylline Injection, USP 25 mg/mL is supplied in single-dose containers 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Hospira, Inc., Lake Forest, IL 60045 USA</p><p>&nbsp;</p><p><strong>Manufacutred By</strong></p><p>Hospira INC, Rocky Mount, United states.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                March 2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">حقن أمينوفيلين، وفقًا لدستور الأدوية الأمريكي (USP)، هي عبارة عن محلول أمينوفيلين معقّم وغير مسبب للحمى موجود في ماء مخصص للحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">توصف حقن أمينوفيلين كعلاج مساعد للناهضات الانتقائية لمستقبلات بيتا-٢ الاستنشاقية والستيرويدات القشرية التي تُستعمل جهازيًا لعلاج مشكلات التنفس التي قد تظهر مع:</p><p dir="RTL">&middot;&nbsp;&nbsp; الربو</p><p dir="RTL">&middot;&nbsp;&nbsp; انتفاخ الرئة</p><p dir="RTL">&middot;&nbsp;&nbsp; الالتهاب الشعبي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استعمال أمينوفيلين</strong></p><p dir="RTL"><strong>يجب عدم استعمال أمينوفيلين إذا كنت تعاني من حساسية تجاه ثيوفيلين، أو الإيثيلين ثنائي الأمين، أو أي من المكونات المدرجة في نهاية هذه النشرة.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">الا<strong>حتياطات عند استعمال أمينوفيلين</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong><em>تحذيرات</em></strong></p><p dir="RTL"><strong>المرض المتزامن:</strong></p><p dir="RTL">ينبغي توخي الحذر الشديد عند استخدام ثيوفيلين في المرضى المصابين بالحالات الإكلينيكية التالية نظرًا لزيادة خطر تفاقم الحالة المتزامنة:</p><p dir="RTL">مرض القرحة الهضمية النشط</p><p dir="RTL">اضطرابات النوبات</p><p dir="RTL">اضطراب ضربات القلب (لا يشمل ذلك اضطراب بطء ضربات القلب)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحالات التي تقلل تصفية ثيوفيلين:</strong></p><p dir="RTL">هناك عدة أسباب يمكن تحديدها بسهولة تتسبب في انخفاض تصفية ثيوفيلين. <strong><em><u>إذا لم يتم تقليل معدل التسريب بشكل مناسب في وجود عوامل الخطر تلك، يمكن أن تحدث سمية ثيوفيلين شديدة ويحتمل أن تكون مميتة.</u></em></strong> يجب إجراء دراسة دقيقة لفوائد ومخاطر استخدام ثيوفيلين، والحاجة إلى مزيد من المراقبة المكثفة لتركيزات ثيوفيلين في مصل الدم في المرضى الذين توجد لديهم عوامل الخطر التالية:</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>العمر</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حديثو الولادة (سواء كانوا مبتسرين أو وُلدوا بعد فترة حمل كاملة)</p><p dir="RTL">الأطفال أقل من عام واحد</p><p dir="RTL">المسنون (أكبر من ٦٠ عامًا)</p><p dir="RTL"><strong>الأمراض المتزامنة</strong></p><p dir="RTL">التورم الرئوي الحاد</p><p dir="RTL">فشل القلب الاحتقاني</p><p dir="RTL">مرض القلب الرئوي</p><p dir="RTL">الحمى؛ درجة حرارة تبلغ ١٠٢&deg; فهرنهايت أو أكبر لمدة ٢٤ ساعة أو أكثر؛ أو ارتفاع درجة الحرارة بقيم أقل لفترات أطول</p><p dir="RTL">قصور الغدة الدرقية</p><p dir="RTL">أمراض الكبد؛ تليف الكبد، التهاب الكبد الوبائي الحاد</p><p dir="RTL">قصور وظائف الكلى في الأطفال الرضع الذين تقل أعمارهم عن ٣ أشهر</p><p dir="RTL">تعفن الدم المصحوب بفشل في أعضاء متعددة</p><p dir="RTL">الصدمة</p><p dir="RTL"><strong>الإقلاع عن التدخين</strong></p><p dir="RTL"><strong>التفاعلات الدوائية</strong></p><p dir="RTL">إضافة عقار من شأنه تثبيط أيض ثيوفيلين (مثل سيميتيدين، إريثرومايسين، تاكرين) أو إيقاف عقار يُستعمل بالتزامن يعمل على تعزيز أيض ثيوفيلين (مثل كاربامازيبين، ريفامبين). (انظر &quot;<strong><em>احتياطات</em></strong>&quot;، &quot;<strong>التفاعلات الدوائية</strong>&quot;، <strong>و&quot;الجدول </strong>۱<strong>&quot;</strong>.)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>عند وجود علامات أو أعراض تدل على حدوث سمية ثيوفيلين:</strong></p><p dir="RTL"><strong><u>في حالة إصابة مريض يتلقى ثيوفيلين بالغثيان أو القيء، أو القيء المتكرر بشكل خاص، أو أي علامات أو أعراض أخرى تتسق مع سمية ثيوفيلين (حتى إذا كان هناك سبب آخر يشتبه فيه)، ينبغي إيقاف التسريب عبر الوريد وقياس تركيز ثيوفيلين في مصل الدم على الفور.</u></strong></p><p dir="RTL"><strong><u>زيادات الجرعة</u></strong></p><p dir="RTL">ينبغي عدم زيادة جرعة ثيوفيلين المخصص للحقن عبر الوريد استجابةً لحدوث تفاقم حاد للأعراض ما لم يكن تركيز ثيوفيلين في مصل الدم في الحالة المستقرة أقل من ١٠ ميكروجرام/مل.</p><p dir="RTL">نظرًا لأن معدل تصفية ثيوفيلين يمكن أن يعتمد على الجرعة (أي أن التركيزات في مصل الدم في الحالة المستقرة يمكن أن تزيد بشكل غير متناسب مع الزيادة في الجرعة)، فإن زيادة الجرعة بناءً على قياس التركيز دون المستوى العلاجي في مصل الدم ينبغي أن تتم بحذر. وبشكل عام، فإن تقييد زيادة معدل التسريب إلى نحو ٢٥ % من معدل التسريب السابق سيقلل من خطر الزيادة المفرطة غير المقصودة لتركيز ثيوفيلين في مصل الدم (انظر &quot;<strong><em>طريقة استخدام أمينوفيلين</em></strong>&quot;، <strong>و&quot;الجدول ٤&quot;</strong>).</p><p dir="RTL"><strong><em>&nbsp;</em></strong></p><p dir="RTL"><strong><em>احتياطات</em></strong></p><p dir="RTL"><strong><u>عامة</u></strong></p><p dir="RTL">ينبغي إجراء دراسة دقيقة للعقاقير العديدة المتفاعلة والحالات الفسيولوجية المتنوعة التي يمكن أن تغير تصفية ثيوفيلين وتتطلب تعديل الجرعة، وذلك قبل البدء في العلاج بثيوفيلين وقبل زيادة جرعته (انظر &quot;<strong><em>تحذيرات</em></strong>&quot;).</p><p dir="RTL"><strong>مراقبة تركيزات ثيوفيلين في مصل الدم:</strong></p><p dir="RTL">إن قياسات تركيز ثيوفيلين في مصل الدم متاحة بسهولة وينبغي استخدامها لتحديد ما إذا كانت الجرعة مناسبة أم لا. وبشكل محدد، ينبغي قياس تركيز ثيوفيلين في مصل الدم كما يلي:</p><p dir="RTL">١. قبل القيام بزيادة الجرعة لتحديد ما إذا كان التركيز في مصل الدم يقع دون المستوى العلاجي أم لا، وذلك للمريض الذي لا تزال تظهر عليه أعراض المرض.</p><p dir="RTL">٢. عند وجود علامات أو أعراض على حدوث سمية ثيوفيلين.</p><p dir="RTL">٣. عند الإصابة بمرض جديد أو تفاقم مرض موجود بشكلٍ متزامن أو عند حدوث تغير في النظام العلاجي للمريض من شأنه أن يغير من تصفية ثيوفيلين (مثل الإصابة بحمى ذات درجة حرارة أكبر من ١٠٢&deg; فهرنهايت تستمر لمدة ٢٤ ساعة أو أكثر، أو التهاب الكبد الوبائي، أو إضافة أي من العقاقير المدرجة في <strong>الجدول</strong> <strong>١</strong> أو إيقافها).</p><p dir="RTL">&nbsp;</p><p dir="RTL">في المرضى الذين لم يتلقوا ثيوفيلين في الـ٢٤ ساعة السابقة، ينبغي قياس التركيز في مصل الدم بعد ٣٠ دقيقة من إكمال جرعة التحميل التي تُحقن عبر الوريد، وذلك لتحديد ما إذا كان التركيز في مصل الدم أقل من ١٠ ميكروجرام/مل مما يشير إلى ضرورة إعطاء جرعة تحميل إضافية أو أكبر من ٢٠ ميكروجرام/مل مما يشير إلى ضرورة تأخير بدء التسريب الثابت عبر الوريد. وبمجرد بدء التسريب، ينبغي إجراء قياس ثان بعد مرور فترة عمر نصف متوقعة واحدة (مثل، حوالي ٤ ساعات في الأطفال من سن عام إلى ٩ أعوام و٨ ساعات في البالغين غير المدخنين؛ للاطلاع على فترات عمر النصف المتوقعة في فئات المرضى الإضافية). ينبغي مقارنة القياس الثاني بالأول لتحديد اتجاه التغير الذي طرأ على التركيز في مصل الدم. وحينئذ يمكن تعديل معدل التسريب قبل الوصول إلى الحالة المستقرة كمحاولة لتجنب الوصول إلى تركيز زائد عن الحد أو تركيز دون المستوى العلاجي لثيوفيلين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أما إذا تلقى المريض ثيوفيلين في الـ٢٤ ساعة السابقة، ينبغي قياس التركيز في مصل الدم قبل إعطاء جرعة تحميل عبر الوريد للتأكد من أن القيام بذلك سيكون آمنًا. وإذا لم تكن هناك حاجة لإعطاء جرعة تحميل (أي كان تركيز ثيوفيلين في مصل الدم يبلغ ١٠ ميكروجرام/مل أو أكبر)، ينبغي إجراء قياس ثان كما هو موضح أعلاه في الوقت المناسب بعد بدء التسريب عبر الوريد. وعلى الجانب الآخر، إذا كانت هناك حاجة لإعطاء جرعة تحميل (انظر &quot;<strong><em>طريقة استخدام أمينوفيلين</em></strong>&quot; للحصول على توجيهات اختيار جرعة التحميل المناسبة)، ينبغي الحصول على عينة دم ثانية بعد إعطاء جرعة التحميل وينبغي الحصول على عينة ثالثة بعد بدء التسريب الثابت بفترة عمر نصف متوقعة واحدة وذلك لتحديد اتجاه التغير الذي طرأ على التركيز في مصل الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بمجرد إكمال الإجراءات الموضحة أعلاه المتعلقة ببدء تسريب ثيوفيلين عبر الوريد، ينبغي الحصول على عينات تالية من مصل الدم لتحديد تركيز ثيوفيلين، وذلك على فترات مدتها ٢٤ ساعة أثناء مدة التسريب. وينبغي زيادة معدل تسريب ثيوفيلين أو تقليله حسبما يقتضي الأمر بناءً على مستويات ثيوفيلين في مصل الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عند وجود علامات أو أعراض على حدوث سمية ثيوفيلين، ينبغي إيقاف التسريب عبر الوريد والحصول على عينة من مصل الدم بأسرع ما يمكن لتحديد تركيز ثيوفيلين، وينبغي تحليلها على الفور وإبلاغ النتيجة إلى الأخصائي الإكلينيكي دون تأخير. في المرضى الذين يشتبه في انخفاض معدل ارتباط الدواء ببروتين المصل لديهم (مثل مرضى تليف الكبد، السيدات أثناء الثلث الثالث من الحمل)، ينبغي قياس تركيز جزء ثيوفيلين غير المرتبط وتعديل الجرعة للوصول إلى تركيز غير مرتبط يتراوح بين ٦-١٢ ميكروجرام/مل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يمكن الاعتماد على تركيزات ثيوفيلين في اللعاب لتعديل الجرعة بدون تقنيات خاصة.</p><p dir="RTL"><br /><strong>الآثار على نتائج الاختبارات المعملية:</strong></p><p dir="RTL">كنتيجة للآثار الدوائية الخاصة بثيوفيلين، فإن تركيزاته في مصل الدم التي تقع في نطاق ١٠‑٢٠ ميكروجرام/مل تزيد بشكل متواضع من تركيز الجلوكوز في البلازما (من متوسط قدره ٨٨ ملجم % إلى ٩٨ ملجم %)، وحمض اليوريك (من متوسط قدره ٤ ملجم/ديسيلتر إلى ٦ ملجم/ديسيلتر)، والأحماض الدهنية الحرة (من متوسط قدره ٤٥١ ميكرو مكافئ/ل إلى ٨٠٠ ميكرو مكافئ/ل)، والكوليسترول الكلي (من متوسط قدره ١٤٠ مقابل ١٦٠ ملجم/ديسيلتر)، والبروتين الدهني مرتفع الكثافة (HDL) (من متوسط قدره ٣٦ إلى ٥٠ ملجم/ديسيلتر)، ونسبة البروتين الدهني مرتفع الكثافة إلى البروتين الدهني منخفض الكثافة (HDL/LDL) (من متوسط قدره ٠.٥ إلى ٠.٧)، ونسبة إفراز الكورتيزول الحر في البول (من متوسط قدره ٤٤ إلى ٦٣ ميكروجرام/٢٤ ساعة). ويمكن أيضًا أن تؤدي تركيزات ثيوفيلين في مصل الدم التي تقع في نطاق ١٠-٢٠ ميكروجرام/مل إلى تقليل تركيزات ثلاثي يودوثيرونين في مصل الدم بشكل عابر (١٤٤ قبل تلقي ثيوفيلين، و١٣١ بعد أسبوع واحد، و١٤٢ نانوجرام/ديسيلتر بعد ٤ أسابيع من تلقي ثيوفيلين). ينبغي الموازنة بين الأهمية الإكلينيكية لهذه التغيرات والفائدة العلاجية المحتملة لثيوفيلين في حالات المرضى الفردية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات</strong><strong> الدوائية مع أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية:</strong></p><p dir="RTL">يتفاعل ثيوفيلين مع مجموعة كبيرة من العقاقير المختلفة. وقد يكون التفاعل متعلق بالديناميكا الدوائية، أي حدوث تغيرات في الاستجابة العلاجية لثيوفيلين أو عقار آخر أو حدوث آثار ضارة دون أن يطرأ تغير على تركيز ثيوفيلين في مصل الدم. ومع ذلك، فكثيرًا ما يكون التفاعل مرتبطًا بالحرائك الدوائية، أي حدوث تغير في معدل تصفية ثيوفيلين بواسطة عقار آخر مما ينتج عنه زيادة أو انخفاض تركيزات ثيوفيلين في مصل الدم. نادرًا ما يؤدي ثيوفيلين إلى تغيير الحرائك الدوائية لعقاقير أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تنطوي العقاقير المدرجة في <strong>الجدول ١</strong> على إمكانية إنتاج تفاعلات ديناميكا دوائية أو حرائك دوائية مهمة إكلينيكيًا مع ثيوفيلين. تفترض المعلومات الموجودة في عمود &quot;التأثير&quot; في <strong>الجدول ١</strong> أن العقار المتفاعل تتم إضافته إلى نظام علاجي بثيوفيلين في الحالة المستقرة. إذا تم بدء العلاج بثيوفيلين في مريض يأخذ بالفعل عقارًا يثبط تصفية ثيوفيلين (مثل سيميتيدين، إريثرومايسين)، فإن جرعة ثيوفيلين اللازمة لتحقيق تركيز علاجي من ثيوفيلين في مصل الدم ستكون أقل من الجرعة المعتادة. وعلى العكس من ذلك، إذا تم بدء العلاج بثيوفيلين في مريض يأخذ بالفعل عقارًا يعزز من تصفية ثيوفيلين (مثل ريفامبين)، فإن جرعة ثيوفيلين اللازمة لتحقيق تركيز علاجي من ثيوفيلين في مصل الدم ستكون أكبر من الجرعة المعتادة. إن إيقاف عقار مصاحب يزيد من تصفية ثيوفيلين من شأنه أن يؤدي إلى تراكم ثيوفيلين إلى مستويات يحتمل أن تكون سامة، ما لم يتم تقليل جرعة ثيوفيلين بشكل مناسب. وكذلك، فإن إيقاف عقار مصاحب يثبط من تصفية ثيوفيلين من شأنه أن يؤدي إلى انخفاض تركيزات ثيوفيلين في مصل الدم، ما لم تتم زيادة جرعة ثيوفيلين بشكل مناسب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">العقاقير المدرجة في <strong>الجدول ٢</strong> إما تم توثيقها على أنها لا تتفاعل مع ثيوفيلين أو لا ينتج عنها تفاعل مهم إكلينيكيًا (أي أن التغيير الذي تحدثه في تصفية ثيوفيلين يقل عن ١٥ %).</p><p dir="RTL">&nbsp;</p><p dir="RTL">تُعد بيانات العقاقير المدرجة في <strong>الجدولين ١ و٢</strong> حالية اعتبارًا من ١ سبتمبر/أيلول ١٩٩٥. يتم الإبلاغ عن التفاعلات الجديدة بشكل مستمر بالنسبة لثيوفيلين، وخصوصًا مع التركيبات الكيميائية الجديدة. <strong><u>ينبغي على الأخصائي الإكلينيكي ألا يفترض أن أحد العقاقير لا يتفاعل مع ثيوفيلين لمجرد كونه غير مدرج في الجدول </u>١<u>.</u></strong> قبل إضافة عقار متوفر حديثًا بالنسبة لمريض يتلقى ثيوفيلين، ينبغي مراجعة نشرة العبوة الخاصة بالعقار الجديد و/أو المراجع الطبية لتحديد ما إذا تم الإبلاغ عن تفاعل بين العقار الجديد وثيوفيلين أم لا.</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>الجدول ١.&nbsp;&nbsp; التفاعلات الدوائية ذات الأهمية الإكلينيكية مع ثيوفيلين*</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:bottom"><p dir="RTL"><strong>العقار</strong></p></td><td style="vertical-align:bottom"><p dir="RTL"><strong>نوع التفاعل</strong></p></td><td style="vertical-align:bottom"><p dir="RTL"><strong>التأثير**</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">أدينوسين</p></td><td style="vertical-align:top"><p dir="RTL">يقوم ثيوفيلين بإحصار مستقبلات</p><p dir="RTL">أدينوسين.</p></td><td style="vertical-align:top"><p dir="RTL">قد يتطلب الأمر جرعات أعلى من أدينوسين لتحقيق التأثير المرغوب.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الكحول</p></td><td style="vertical-align:top"><p dir="RTL">تؤدي جرعة فردية كبيرة من الكحول</p><p dir="RTL">(٣ مل/كلجم من الويسكي) إلى تقليل</p><p dir="RTL">تصفية ثيوفيلين لما يصل إلى ٢٤ ساعة.</p></td><td style="vertical-align:top"><p dir="RTL">زيادة بنسبة ٣٠ %</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">ألوبورينول</p></td><td style="vertical-align:top"><p dir="RTL">يقلل تصفية ثيوفيلين عند إعطائه بجرعات تبلغ ٦٠٠ ملجم/يوم أو أكبر.</p></td><td style="vertical-align:top"><p dir="RTL">زيادة بنسبة ٢٥ %</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">أمينوجلوتيثيميد</p></td><td style="vertical-align:top"><p dir="RTL">يزيد من تصفية ثيوفيلين عن طريق</p><p dir="RTL">تحفيز نشاط الإنزيمات الميكروسومية.</p></td><td style="vertical-align:top"><p dir="RTL">انخفاض بنسبة ٢٥ %</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">كاربامازبين</p></td><td style="vertical-align:top"><p dir="RTL">مماثل لأمينوجلوتيثيميد.</p></td><td style="vertical-align:top"><p dir="RTL">انخفاض بنسبة ٣٠ %</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">سيميتيدين</p></td><td style="vertical-align:top"><p dir="RTL">يقلل تصفية ثيوفيلين عن طريق تثبيط السيتوكروم P450 1A2.</p></td><td style="vertical-align:top"><p dir="RTL">زيادة بنسبة ٧٠ %</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">سيبروفلوكساسين</p></td><td style="vertical-align:top"><p dir="RTL">مماثل لسيميتيدين.&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">زيادة بنسبة ٤٠ %</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">كلاريثرومايسين</p></td><td style="vertical-align:top"><p dir="RTL">مماثل لإريثرومايسين.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">زيادة بنسبة ٢٥ %</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">ديازيبام</p></td><td style="vertical-align:top"><p dir="RTL">تزيد البنزوديازيبينات من تركيزات أدينوسين في الجهاز العصبي المركزي، وأدينوسين هو مثبط قوي للجهاز العصبي المركزي، بينما يقوم ثيوفيلين بإحصار مستقبلات أدينوسين.</p></td><td style="vertical-align:top"><p dir="RTL">قد يتطلب الأمر جرعات أكبر من ديازيبام</p><p dir="RTL">لإحداث المستوى المرغوب من التهدئة. قد يؤدي إيقاف ثيوفيلين دون تقليل جرعة ديازيبام إلى حدوث تثبيط تنفسي.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">ديسلفيرام</p></td><td style="vertical-align:top"><p dir="RTL">يقلل تصفية ثيوفيلين عن طريق تثبيط عمليتي إضافة الهيدروكسيل ونزع الميثيل.</p></td><td style="vertical-align:top"><p dir="RTL">زيادة بنسبة ٥٠ %</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">إينوكساسين</p></td><td style="vertical-align:top"><p dir="RTL">مماثل لسيميتيدين.&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">زيادة بنسبة ٣٠٠ %</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">إيفيدرين</p></td><td style="vertical-align:top"><p dir="RTL">آثار تآزرية على الجهاز العصبي المركزي.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">زيادة معدل تكرار الغثيان،</p><p dir="RTL">والعصبية، والأرق.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">إريثرومايسين</p></td><td style="vertical-align:top"><p dir="RTL">يقلل ناتج أيض إريثرومايسين من تصفية ثيوفيلين عن طريق تثبيط</p><p dir="RTL">السيتوكروم P450 3A3.</p></td><td style="vertical-align:top"><p dir="RTL">زيادة بنسبة ٣٥ %. وتقل تركيزات إريثرومايسين</p><p dir="RTL">في مصل الدم في الحالة المستقرة بكمية مماثلة.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">إستروجين</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">وسائل منع الحمل التي تؤخذ عن طريق الفم وتحتوي على إستروجين تقلل من تصفية ثيوفيلين بطريقة معتمدة على الجرعة.</p><p dir="RTL">تأثير البروجستيرون على تصفية ثيوفيلين غير معروف.</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">زيادة بنسبة ٣٠ %</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">فلورازيبام</p></td><td style="vertical-align:top"><p dir="RTL">مماثل لديازيبام.</p></td><td style="vertical-align:top"><p dir="RTL">مماثل لديازيبام.</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>الجدول ١.&nbsp;&nbsp; التفاعلات الدوائية ذات الأهمية الإكلينيكية مع ثيوفيلين* (تتمة)</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:bottom"><p dir="RTL"><strong>العقار</strong></p></td><td style="vertical-align:bottom"><p dir="RTL"><strong>نوع التفاعل</strong></p></td><td style="vertical-align:bottom"><p dir="RTL"><strong>التأثير**</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">فلوفوكسامين</p></td><td style="vertical-align:top"><p dir="RTL">مماثل لسيميتيدين.</p></td><td style="vertical-align:top"><p dir="RTL">مماثل لسيميتيدين.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">هالوثان</p></td><td style="vertical-align:top"><p dir="RTL">يؤدي هالوثان إلى إصابة عضلة القلب بحساسية</p><p dir="RTL">تجاه الكاتيكولامينات، يزيد</p><p dir="RTL">ثيوفيلين من إطلاق الكاتيكولامينات</p><p dir="RTL">داخلية المنشأ.</p></td><td style="vertical-align:top"><p dir="RTL">زيادة خطر الإصابة باضطراب ضربات</p><p dir="RTL">القلب البطيني.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">إنترفيرون، ألفا-أ</p><p dir="RTL">بشري مأشوب</p></td><td style="vertical-align:top"><p dir="RTL">يقلل من تصفية ثيوفيلين.</p></td><td style="vertical-align:top"><p dir="RTL">زيادة بنسبة ١٠٠ %</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">أيزوبروتيرينول (عن طريق الوريد)</p></td><td style="vertical-align:top"><p dir="RTL">يزيد من تصفية ثيوفيلين.</p></td><td style="vertical-align:top"><p dir="RTL">انخفاض بنسبة ٢٠ %</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">كيتامين</p></td><td style="vertical-align:top"><p dir="RTL">دوائي</p></td><td style="vertical-align:top"><p dir="RTL">قد يخفض من حد النوبات</p><p dir="RTL">الخاص بثيوفيلين.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الليثيوم</p></td><td style="vertical-align:top"><p dir="RTL">يزيد ثيوفيلين من تصفية الليثيوم الكلوية.&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">زادت جرعة الليثيوم اللازمة للوصول إلى تركيز علاجي في مصل الدم بمتوسط ٦٠ %.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">لورازيبام</p></td><td style="vertical-align:top"><p dir="RTL">مماثل لديازيبام.</p></td><td style="vertical-align:top"><p dir="RTL">مماثل لديازيبام.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">ميثوتريكسات (MTX)</p></td><td style="vertical-align:top"><p dir="RTL">يقلل من تصفية ثيوفيلين.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">زيادة بنسبة ٢٠ % بعد جرعة منخفضة من ميثوتريكسات، قد يكون لجرعة أعلى من ميثوتريكسات تأثيرًا أكبر.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">ميكسيليتين</p></td><td style="vertical-align:top"><p dir="RTL">مماثل لديسلفيرام.</p></td><td style="vertical-align:top"><p dir="RTL">زيادة بنسبة ٨٠ %</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">ميدازولام</p></td><td style="vertical-align:top"><p dir="RTL">مماثل لديازيبام.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">مماثل لديازيبام.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">موريسيزين</p></td><td style="vertical-align:top"><p dir="RTL">يزيد من تصفية ثيوفيلين.</p></td><td style="vertical-align:top"><p dir="RTL">انخفاض بنسبة ٢٥ %</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">بانكورونيوم</p></td><td style="vertical-align:top"><p dir="RTL">قد يناهض ثيوفيلين</p><p dir="RTL">الآثار الحاصرة للنقل العصبي العضلي غير المزيلة للاستقطاب؛ ومن المحتمل أن يكون ذلك بسبب تثبيط إنزيم فوسفودايستراز.</p></td><td style="vertical-align:top"><p dir="RTL">قد يتطلب الأمر جرعة أكبر من بانكورونيوم لتحقيق الإحصار العصبي العضلي.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">بنتوكسيفيلين</p></td><td style="vertical-align:top"><p dir="RTL">يقلل من تصفية ثيوفيلين.</p></td><td style="vertical-align:top"><p dir="RTL">زيادة بنسبة ٣٠ %</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">فينوباربيتال (PB)</p></td><td style="vertical-align:top"><p dir="RTL">مماثل لأمينوجلوتيثيميد.</p></td><td style="vertical-align:top"><p dir="RTL">انخفاض بنسبة ٢٥ % بعد أسبوعين من العلاج المتزامن بفينوباربيتال.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">فينيتوين</p></td><td style="vertical-align:top"><p dir="RTL">يزيد فينيتوين من تصفية</p><p dir="RTL">ثيوفيلين عن طريق زيادة نشاط</p><p dir="RTL">الإنزيمات الميكروسومية. يقلل ثيوفيلين</p><p dir="RTL">من امتصاص فينيتوين.</p></td><td style="vertical-align:top"><p dir="RTL">تنخفض تركيزات ثيوفيلين وفينيتوين في مصل الدم بنسبة ٤٠ % تقريبًا.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">بروبافينون</p></td><td style="vertical-align:top"><p dir="RTL">يقلل من تصفية ثيوفيلين و</p><p dir="RTL">يحدث تفاعل دوائي.</p></td><td style="vertical-align:top"><p dir="RTL">زيادة بنسبة ٤٠ %. وقد يقلل التأثير الحاصر لمستقبلات بيتا-٢</p><p dir="RTL">من فعالية ثيوفيلين.</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>الجدول ١.&nbsp;&nbsp; التفاعلات الدوائية ذات الأهمية الإكلينيكية مع ثيوفيلين* (تتمة)</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>العقار</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>نوع التفاعل</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>التأثير**</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">بروبرانولول</p></td><td style="vertical-align:top"><p dir="RTL">مماثل لسيميتيدين ويحدث تفاعل دوائي.</p></td><td style="vertical-align:top"><p dir="RTL">زيادة بنسبة ١٠٠ %. وقد يقلل التأثير الحاصر لمستقبلات بيتا-٢</p><p dir="RTL">من فعالية ثيوفيلين.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">ريفامبين</p></td><td style="vertical-align:top"><p dir="RTL">يزيد من تصفية ثيوفيلين عن طريق</p><p dir="RTL">زيادة نشاط السيتوكروم P450&rlm; 1A2 و3A3.</p></td><td style="vertical-align:top"><p dir="RTL">انخفاض بنسبة ٢٠-٤٠ %</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">سلفينبيرازون</p></td><td style="vertical-align:top"><p dir="RTL">يزيد من تصفية ثيوفيلين عن طريق</p><p dir="RTL">زيادة عمليتي نزع الميثيل وإضافة الهيدروكسيل. يقلل التصفية الكلوية لثيوفيلين.</p></td><td style="vertical-align:top"><p dir="RTL">انخفاض بنسبة ٢٠ %</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">تاكرين</p></td><td style="vertical-align:top"><p dir="RTL">مماثل لسيميتيدين، إضافة إلى أنه يزيد من التصفية الكلوية لثيوفيلين.</p></td><td style="vertical-align:top"><p dir="RTL">زيادة بنسبة ٩٠ %</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">ثيابيندازول</p></td><td style="vertical-align:top"><p dir="RTL">يقلل من تصفية ثيوفيلين.</p></td><td style="vertical-align:top"><p dir="RTL">زيادة بنسبة ١٩٠ %</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">تيكلوبيدين</p></td><td style="vertical-align:top"><p dir="RTL">يقلل من تصفية ثيوفيلين.</p></td><td style="vertical-align:top"><p dir="RTL">زيادة بنسبة ٦٠ %</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">تروليندومايسين</p></td><td style="vertical-align:top"><p dir="RTL">مماثل لإريثرومايسين.</p></td><td style="vertical-align:top"><p dir="RTL">زيادة بنسبة ٣٣-١٠٠ % وفقًا لجرعة تروليندومايسين.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">فيراباميل</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">مماثل لديسلفيرام.</p></td><td style="vertical-align:top"><p dir="RTL">زيادة بنسبة ٢٠ %</p></td></tr></tbody></table><p dir="RTL"><strong>*</strong>&nbsp;&nbsp;&nbsp; يُرجى الرجوع إلى<strong> <em>&quot;احتياطات&quot;</em>، &quot;التفاعلات الدوائية&quot; </strong>للاطلاع على مزيد من المعلومات بخصوص الجدول.</p><p dir="RTL"><strong>**</strong>&nbsp;&nbsp; متوسط التأثير على تركيز ثيوفيلين في الحالة المستقرة أو تأثير إكلينيكي آخر للتفاعلات الدوائية. قد يتعرض المرضى الفرديون لتغيرات في تركيز ثيوفيلين في مصل الدم بقيم أكبر من القيمة المدرجة.</p><p>&nbsp;</p><p dir="RTL"><strong>الجدول </strong>٢<strong>.</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>العقاقير التي تم توثيقها على أنها لا تتفاعل مع ثيوفيلين أو</strong></p><p dir="RTL"><strong>العقاقير التي لا ينتج عنها تفاعل مهم إكلينيكيًا مع ثيوفيلين*</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">ألبوتيرول،</p><p dir="RTL">&nbsp;&nbsp; الجهازي والاستنشاقي</p><p dir="RTL">أموكسيسيلين</p><p dir="RTL">أمبيسيلين،</p><p dir="RTL">&nbsp;&nbsp; مع سولباكتام أو بدونه</p><p dir="RTL">أتينولول</p><p dir="RTL">أزيثرومايسين</p><p dir="RTL">كافيين،</p><p dir="RTL">&nbsp;&nbsp; التناول في صورة غذائية</p><p dir="RTL">سيفاكلور</p><p dir="RTL">كو-تريموكسازول</p><p dir="RTL">&nbsp;&nbsp; (تريميثوبريم وسلفاميثوكسازول)</p><p dir="RTL">ديلتيازيم</p><p dir="RTL">ديريثرومايسين</p><p dir="RTL">إينفلوران</p><p dir="RTL">فاموتيدين</p><p dir="RTL">فيلوديبين</p><p dir="RTL">فيناسترايد</p><p dir="RTL">هيدروكورتيزون</p><p dir="RTL">أيزوفلوران</p><p dir="RTL">أيزونيازيد</p><p dir="RTL">إسراديبين</p><p dir="RTL">لقاح الإنفلونزا</p><p dir="RTL">كيتوكونازول</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">لوميفلوكساسين</p><p dir="RTL">ميبيندازول</p><p dir="RTL">ميدروكسي بروجستيرون</p><p dir="RTL">ميثيل بريدنيزولون</p><p dir="RTL">ميترونيدازول</p><p dir="RTL">ميتوبرولول</p><p dir="RTL">نادولول</p><p dir="RTL">نيفيديبين</p><p dir="RTL">نيزاتيدين</p><p dir="RTL">نورفلوكساسين</p><p dir="RTL">أوفلوكساسين</p><p dir="RTL">أوميبرازول</p><p dir="RTL">بريدنيزون، بريدنيزولون</p><p dir="RTL">رانيتيدين</p><p dir="RTL">ريفابوتين</p><p dir="RTL">روكسيثرومايسين</p><p dir="RTL">سوربيتول</p><p dir="RTL">&nbsp; (لا تقوم الجرعات المسهلة بتثبيط</p><p dir="RTL">&nbsp; امتصاص ثيوفيلين)</p><p dir="RTL">سوكرالفات</p><p dir="RTL">تيربوتالين، الجهازي</p><p dir="RTL">تيرفينادين</p><p dir="RTL">تتراسايكلين</p><p dir="RTL">توكاينيد</p></td></tr></tbody></table><p dir="RTL"><strong>* </strong>يُرجى الرجوع إلى<strong> <em>&quot;احتياطات&quot;</em>، &quot;التفاعلات الدوائية&quot; </strong>للاطلاع على معلومات بخصوص الجدول.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تأثير العقاقير الأخرى على قياسات تركيز ثيوفيلين في مصل الدم:</strong></p><p dir="RTL">إن أغلب مقايسات ثيوفيلين مصل الدم التي تمت في الاستخدام الإكلينيكي هي مقايسات مناعية مخصصة لثيوفيلين. ولا يتم اكتشاف مركبات الزانثاين الأخرى، مثل كافيين وديفيلين وبنتوكسيفيلين، عن طريق هذه المقايسات. إلا أن بعض العقاقير (مثل سيفازولين، سيفالوثين)، قد تتداخل مع بعض أساليب الاستشراب السائل عالي الأداء (HPLC). قد تتسبب نواتج أيض كافيين وزانثاين في أن تكون القراءة الناتجة عن بعض الوسائل المكتبية التي تستخدم مواد كاشفة جافة أعلى من قيمة تركيز ثيوفيلين الفعلي في مصل الدم، وذلك في حديثي الولادة أو المرضى المصابين بخلل في وظائف الكلى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL"><strong>الاستعمال لدى الأطفال:</strong></p><p dir="RTL">يعتبر ثيوفيلين آمنًا وفعالًا لعلاج دواعي الاستعمال المعتمدة في المرضى من الأطفال (انظر <strong><em>&quot;دواعي الاستعمال والاستخدام&quot;</em></strong>). يجب أن يتم اختيار معدل التسريب الثابت لثيوفيلين المخصص للحقن عبر الوريد بحرص في المرضى الأطفال، نظرًا لأن معدل تصفية ثيوفيلين يتفاوت بشكل كبير عبر المدى العمري لحديثي الولادة حتى المراهقين (انظر <strong><em>&quot;الصيدلة الإكلينيكية&quot;</em></strong>، &nbsp;<strong><em>&quot;تحذيرات&quot;</em></strong>، و<strong><em>&quot;طريقة استخدام أمينوفيلين&quot;</em></strong>، <strong>&quot;الجدول ٣&quot;</strong>). ونظرًا لعدم اكتمال نمو مسارات أيض ثيوفيلين في المرضى الأطفال الذين تقل أعمارهم عن عام واحد، يجب إيلاء اهتمام خاص لاختيار الجرعة وإجراء مراقبة متكررة لتركيزات ثيوفيلين في مصل الدم عند وصف ثيوفيلين للمرضى الأطفال في هذه الفئة العمرية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الاستعمال لدى المسنين:</strong></p><p dir="RTL">يواجه المرضى المسنون خطرًا أكبر بشكل واضح للتعرض لسمية خطيرة من ثيوفيلين مقارنةً بالمرضى الأصغر عمرًا نظرًا للتغيرات في الحرائك الدوائية والديناميكا الدوائية المرتبطة بالتقدم في العمر. تقل تصفية ثيوفيلين في المرضى الذين تزيد أعمارهم عن ٦٠ عامًا، مما يؤدي إلى زيادة تركيزات ثيوفيلين في مصل الدم استجابة لمعدل تسريب معين لثيوفيلين. وقد ينخفض معدل الارتباط بالبروتين في المسنين، مما يتنج عنه نسبة أكبر من التركيز الكلي لثيوفيلين في مصل الدم في صورة الشكل غير المرتبط النشط دوائيًا. ويبدو كذلك أن المرضى المسنين يكونون أكثر حساسية للآثار السامة الخاصة بثيوفيلين بعد التعرض المزمن لجرعة مفرطة مقارنةً بالمرضى الأصغر عمرًا. ولهذه الأسباب، فإن الحد الأقصى لمعدل تسريب ثيوفيلين في المرضى الأكبر من ٦٠ عامًا ينبغي ألا يتخطى عادةً<br />١٧ ملجم/ساعة (٢١ ملجم/ساعة في صورة أمينوفيلين) إلا إذا استمرت الأعراض في الظهور على المريض وكانت ذروة تركيز ثيوفيلين في مصل الدم في الحالة المستقرة أقل من ١٠ ميكروجرام/مل (انظر <strong><em>&quot;طريقة استخدام أمينوفيلين&quot;</em></strong>). ينبغي توخي الحذر عند وصف معدلات تسريب ثيوفيلين التي تزيد عن ١٧ ملجم/ساعة (٢١ ملجم/ساعة في صورة أمينوفيلين) للمرضى المسنين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل </strong><strong>والرضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل: </strong></p><p dir="RTL">لم يتم إجراء دراسات وافية ومراقبة بشكل جيد على السيدات الحوامل. وإضافة إلى ذلك، لم يتم إجراء دراسات متعلقة بالإمساخ على حيوانات غير قارضة (مثل الأرانب). لم يظهر أن ثيوفيلين له تأثير ماسخ على فئران CD-1 عند إعطاء جرعات عن طريق الفم تصل إلى ٤٠٠ ملجم/كلجم، حوالي ضعفي جرعة البشر على أساس ملجم/م<sup>٢</sup>، أو على جرذان CD-1 عند إعطاء جرعات عن طريق الفم تصل إلى ٢٦٠ ملجم/كلجم، حوالي ٣ أضعاف الجرعة الموصى بها للبشر على أساس ملجم/م<sup>٢</sup>.&nbsp; تمت ملاحظة سمية جنينية في الجرذان، مع غياب السمية لدى الأمهات، عند إعطاء جرعة تبلغ ٢٢٠ ملجم/كلجم.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأمهات المرضعات:</strong></p><p dir="RTL">يتم إفراز ثيوفيلين في لبن الثدي وقد يسبب تهيجًا أو علامات أخرى على حدوث سمية خفيفة في أطفال البشر الرضع. يعادل تركيز ثيوفيلين في لبن الثدي تقريبًا تركيزه في مصل الدم لدى الأم. فالرضيع الذي يتناول لترًا من لبن الثدي يحتوي على ١٠‑٢٠ ميكروجرام/مل من ثيوفيلين في اليوم، سوف يتلقى على الأرجح ١٠-٢٠ ملجم من ثيوفيلين في اليوم. ومن غير المرجح حدوث آثار ضارة خطيرة لدى الرضيع إلا إذا كانت تركيزات ثيوفيلين في مصل الدم لدى الأم سامة.</p><p dir="RTL"><strong>التسرطن، والتطفير، وضعف الخصوبة:</strong></p><p dir="RTL">تم إجراء دراسات سرطنة طويلة الأمد على الفئران (جرعات عن طريق الفم تتراوح بين ٣٠-١٥٠ ملجم/كلجم) والجرذان (جرعات عن طريق الفم تتراوح بين ٥-٧٥ ملجم/كلجم). ولا تزال النتائج معلقة.</p><p dir="RTL">دُرست ثيوفيلين في نظام اختبار آيمز باستخدام بكتيريا السالمونيلا، وكذلك أنظمة اختبار الوراثيات الخلوية <em>داخل الجسم</em> و<em>في المعمل</em> والنواة الدقيقة ومبيض الهامستر الصيني ولم يظهر أنه سام للجينات.</p><p dir="RTL">في دراسة تكاثر مستمرة استغرقت ١٤ أسبوعًا، أدى ثيوفيلين المُعطى لأزواج من فئران B6C3F<sub>1</sub> المتزاوجة بجرعات عن طريق الفم تبلغ ١٢٠ و٢٧٠ و٥٠٠ ملجم/كلجم (حوالي ١.٠-٣.٠ أضعاف جرعة البشر على أساس ملجم/م<sup>٢</sup>) إلى إضعاف الخصوبة، وهو ما دلت عليه الانخفاضات في أعداد الصغار الأحياء لكل مجموعة ولادة والانخفاضات في متوسط عدد مرات الولادة لكل زوج خصب والزيادات في فترة الحمل عند الجرعات العالية، بالإضافة إلى الانخفاضات في نسب الصغار المولودة حية عند الجرعات المتوسطة والعالية. وفي دراسات سمية استغرقت ١٣ أسبوعًا، أعطي ثيوفيلين إلى جرذان F344 وفئران B6C3F<sub>1</sub> بجرعات عن طريق الفم تتراوح بين ٤٠-٣٠٠ ملجم/كلجم (حوالي ضعفي جرعة البشر على أساس ملجم/م<sup>٢</sup>). وعند الجرعات العالية، لوحظت سمية جهازية في كلٍ من الفصيلتين بما في ذلك انخفاضات في وزن الخصيتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير</strong><strong> أمينوفيلين على القيادة واستخدام الآلات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا ينطبق.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اعتبارات عامة:</strong></p><p dir="RTL">إن تركيز ثيوفيلين في مصل الدم في الحالة المستقرة هو عبارة عن دالة لمعدل التسريب ومعدل تصفية ثيوفيلين في المريض الفردي. ونظرًا للاختلافات الفردية الملحوظة في معدل تصفية ثيوفيلين، فإن الجرعة المطلوبة للوصول إلى تركيز ثيوفيلين في المصل في نطاق<br />١٠-٢٠ ميكروجرام/مل تتفاوت بمعدل أربعة أضعاف بين المرضى المتشابهين بخلاف ذلك في غياب العوامل المعروف عنها تغيير تصفية ثيوفيلين. بالنسبة لفئة معينة، لا توجد جرعة فردية من ثيوفيلين توفر تركيزات آمنة وفعالة في مصل الدم بالنسبة لجميع المرضى. واستعمال جرعة ثيوفيلين الوسيطة اللازمة للوصول إلى تركيز علاجي لثيوفيلين في مصل الدم في فئة معينة قد ينتج عنه تركيزات لثيوفيلين في مصل الدم تقع دون المستوى العلاجي أو تكون محتملة السمية في المرضى الفرديين. <strong><u>يجب أن يتم تحديد جرعة ثيوفيلين بشكل فردي استنادًا إلى قياسات تركيز ثيوفيلين في مصل الدم من أجل الوصول إلى جرعة توفر أقصى فائدة ممكنة مع أدنى حد من خطر الآثار الضارة.</u></strong></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">عند استخدام ثيوفيلين في صورة موسع حاد للشعب الهوائية، فإن أفضل طريقة لتحقيق هدف الوصول إلى تركيز علاجي في مصل الدم تكون من خلال جرعة تحميل تُعطى عن طريق الوريد. ونظرًا للتوزيع السريع في سوائل الجسم، فإن تركيز العقار في مصل الدم (C) الذي يتم الوصول إليه من جرعة تحميل (LD) مبدئية يكون مرتبطًا بشكل رئيسي بحجم التوزيع (V)، وهو المساحة الظاهرة التي ينتشر فيها العقار:</p><p dir="RTL">C = LD/V</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تم الافتراض أن متوسط حجم التوزيع يبلغ حوالي ٠.٥ ل/كلجم (النطاق الفعلي يتراوح بين ٠.٣ إلى ٠.٧ ل/كلجم)، فإن كل ملجم/كلجم (وزن الجسم المثالي) يتم إعطاؤه من ثيوفيلين في صورة جرعة تحميل على مدار ٣٠ دقيقة ستنتج عنه زيادة بمتوسط ٢ ميكروجرام/مل في تركيز ثيوفيلين في مصل الدم. ولذلك، بالنسبة لمريض لم يتلق ثيوفيلين في الـ٢٤ ساعة السابقة، فإن جرعة تحميل من ثيوفيلين المخصص للحقن عبر الوريد تبلغ ٤.٦ ملجم/كلجم (٥.٧ ملجم/كلجم في صورة أمينوفيلين)، محسوبة على أساس وزن الجسم المثالي ومعطاة على مدار ٣٠ دقيقة، سينتج عنها في المتوسط تركيز في مصل الدم يبلغ بعد التوزيع ١٠ ميكروجرام/مل بحد أقصى مع نطاق يتراوح بين ٦-١٦ ميكروجرام/مل. عندما يصبح إعطاء جرعة تحميل أمرًا ضروريًا بالنسبة لمريض تلقى ثيوفيلين بالفعل، فإن تقدير التركيز في مصل الدم بناءً على التاريخ يكون أمرًا غير موثوق، ويجب إجراء تحديد فوري لمستوى العقار في مصل الدم. وبعد ذلك، يمكن تحديد جرعة التحميل كما يلي:</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; D &rlm;= (C المرغوب - &rlm;C&rlm; المقاس) (V)</p><p dir="RTL">حيث D هي جرعة التحميل، وC هو تركيز ثيوفيلين في مصل الدم، وV هو حجم التوزيع. يمكن افتراض أن متوسط حجم التوزيع يبلغ ٠.٥ ل/كلجم، وينبغي أن يكون التركيز المرغوب في مصل الدم متحفظًا (مثال، ١٠ ميكروجرام/مل) ليسمح بالتفاوت في حجم التوزيع. <strong><u>ينبغي عدم إعطاء جرعة تحميل قبل قياس تركيز ثيوفيلين في مصل الدم إذا كان المريض قد تلقى أي مقدار من ثيوفيلين في الـ٢٤ ساعة السابقة.</u></strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن استخدام تركيز العقار في مصل الدم الذي يتم قياسه بعد مرور ٣٠ دقيقة على جرعة تحميل عن طريق الوريد، عندما يكون التوزيع قد اكتمل، لتقييم الحاجة إلى جرعات تحميل تالية وحجم تلك الجرعات، إن استدعى الأمر ذلك إكلينيكيًا، ولتوجيه العلاج المستمر. وبمجرد الوصول إلى تركيز يتراوح بين ١٠ إلى ١٥ ميكروجرام/مل في مصل الدم باستخدام جرعة (جرعات) تحميل، يتم بدء تسريب ثابت عن طريق الوريد. يعتمد معدل الاستعمال على متوسط معاملات الحرائك الدوائية لفئة المرضى المعنية، ويتم حسابه للوصول إلى تركيز مستهدف في مصل الدم يبلغ ١٠ ميكروجرام/مل (انظر <strong>&quot;الجدول ٣&quot;</strong>). على سبيل المثال، في البالغين غير المدخنين، فإن بدء التسريب الثابت عن طريق الوريد لثيوفيلين بمقدار ٠.٤ ملجم/كلجم/ساعة (٠.٥ ملجم/كلجم/ساعة في صورة أمينوفيلين) بعد إكمال جرعة التحميل، سيؤدي في المتوسط إلى الوصول إلى تركيز في الحالة المستقرة يبلغ ١٠ ميكروجرام/مل مع نطاق يتراوح بين ٧-٢٦ ميكروجرام/مل. يتماثل متوسط ونطاق التركيزات في مصل الدم في الحالة المستقرة عندما يتم إعطاء الطفل العادي (بعمر من عام واحد إلى ٩ أعوام) جرعة تحميل تبلغ ٤.٦ ملجم/كلجم من ثيوفيلين (٥.٧ ملجم/كلجم في صورة أمينوفيلين) يتبعها تسريب ثابت عن طريق الوريد يبلغ ٠.٨ ملجم/كلجم/ساعة (١.٠ ملجم/كلجم/ساعة في صورة أمينوفيلين). نظرًا لوجود تفاوت كبير بين المرضى في تصفية ثيوفيلين، فإن تركيزات العقار في مصل الدم سوف ترتفع أو تنخفض عندما يختلف معدل تصفية المريض بشكل كبير عن القيمة المتوسطة المستخدمة لحساب معدل التسريب المبدئي لفئة المرضى المعنية. لذلك، ينبغي إجراء قياس ثان للتركيز في مصل الدم بعد مرور فترة عمر نصف متوقعة واحدة بعد بدء التسريب الثابت (مثل، حوالي ٤ ساعات للأطفال من سن عام إلى ٩ أعوام و٨ ساعات للبالغين غير المدخنين؛ للاطلاع على فترات عمر النصف المتوقعة في فئات المرضى الإضافية)، وذلك لتحديد إذا كان التركيز يتراكم أو ينخفض عن مستواه بعد جرعة التحميل. وإذا كان المستوى ينخفض نتيجة لمعدل تصفية أعلى من المتوسط، يمكن إعطاء جرعة تحميل إضافية و/أو زيادة معدل التسريب. وعلى العكس من ذلك، إذا أظهرت العينة الثانية مستوى أعلى، يمكن افتراض حدوث تراكم للعقار، وينبغي عندئذٍ تقليل معدل التسريب قبل أن يتجاوز مستوى التركيز ٢٠ ميكروجرام/مل. يتم الحصول على عينة إضافية بعد ذلك بـ١٢ إلى ٢٤ ساعة لتحديد ما إذا كان الأمر يتطلب المزيد من التعديل، ثم تؤخذ عينات على فترات بمعدل ٢٤ ساعة للتعديل مقابل التغيرات، إذا حدثت. سوف تمنع هذه الطريقة التجريبية، بناءً على متوسط معاملات الحرائك الدوائية، حدوث تذبذبات كبيرة في التركيز في مصل الدم أثناء الفترة الأكثر حرجًا من مسار علاج المريض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في المرضى المصابين بمرض القلب الرئوي أو انهيار معاوضة القلب أو خلل في وظائف الكبد، أو في المرضى الذين يتناولون عقاقير تقلل من تصفية ثيوفيلين بشكل كبير (مثل سيميتيدين)، ينبغي ألا يتجاوز معدل التسريب المبدئي لثيوفيلين ١٧ ملجم/ساعة (٢١ ملجم/ساعة في صورة أمينوفيلين) ما لم تكن هناك إمكانية لمراقبة التركيزات في مصل الدم على فترات تبلغ ٢٤ ساعة. ففي هؤلاء المرضى، قد يستغرق الأمر ٥ أيام قبل الوصول إلى الحالة المستقرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوزع ثيوفيلين بشكل ضعيف في دهون الجسم، ولذلك ينبغي حساب جرعة ملجم/كلجم على أساس وزن الجسم المثالي.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الجدول ٣</strong> يحتوي على معدلات تسريب ثيوفيلين المبدئية، بعد جرعة تحميل مناسبة، الموصى بها للمرضى في فئات عمرية وظروف إكلينيكية مختلفة. <strong>الجدول ٤</strong> يحتوي على التوصيات الخاصة بالتعديل النهائي لجرعة ثيوفيلين استنادًا إلى تركيزات ثيوفيلين في مصل الدم. <strong><u>عند تطبيق هذه التوصيات العامة لمعايرة الجرعة على المرضى الفرديين، يجب الأخذ في الاعتبار الخصائص الإكلينيكية الفريدة لكل مريض. وبشكل عام، ينبغي أن تعمل هذه التوصيات كحد أعلى لتعديلات الجرعات من أجل تقليل خطر وقوع الأحداث الضارة محتملة الخطورة المرتبطة بالزيادات الكبيرة غير المتوقعة في تركيز ثيوفيلين في مصل الدم.</u></strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجدول ٣.&nbsp;&nbsp; معدلات تسريب ثيوفيلين المبدئية بعد جرعة تحميل مناسبة.</strong></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>فئة المرضى</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>العمر</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>معدل تسريب ثيوفيلين (ملجم/كلجم/ساعة)*&dagger;&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">حديثو الولادة</p></td><td style="vertical-align:top"><p dir="RTL">عمر ما بعد الولادة حتى ٢٤ يومًا</p><p dir="RTL">عمر ما بعد الولادة بعد ٢٤ يومًا</p></td><td style="vertical-align:top"><p dir="RTL">١ ملجم/كلجم كل ١٢ ساعة/&Dagger;</p><p dir="RTL">١.٥ ملجم/كلجم كل ١٢ ساعة/&Dagger;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الرضع</p></td><td style="vertical-align:top"><p dir="RTL">بعمر ٦-٥٢ أسبوعًا</p></td><td style="vertical-align:top"><p dir="RTL">ملجم/كلجم/ساعة = (٠.٠٠٨)(العمر بالأسابيع) + ٠.٢١</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الأطفال الصغار</p></td><td style="vertical-align:top"><p dir="RTL">١-٩ أعوام</p></td><td style="vertical-align:top"><p dir="RTL">٠.٨</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الأطفال الأكبر</p></td><td style="vertical-align:top"><p dir="RTL">٩-١٢ عامًا</p></td><td style="vertical-align:top"><p dir="RTL">٠.٧</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">المراهقون</p><p dir="RTL">&nbsp; (مدخنو السجائر أو</p><p dir="RTL">&nbsp; الماريجوانا)</p></td><td style="vertical-align:top"><p dir="RTL">١٢-١٦ عامًا</p></td><td style="vertical-align:top"><p dir="RTL">٠.٧</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">المراهقون (غير المدخنين)</p></td><td style="vertical-align:top"><p dir="RTL">١٢-١٦ عامًا</p></td><td style="vertical-align:top"><p dir="RTL">٠.٥ &sect;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">البالغون</p><p dir="RTL">&nbsp; (غير المدخنين الأصحاء</p><p dir="RTL">&nbsp; بخلاف ذلك)</p></td><td style="vertical-align:top"><p dir="RTL">١٦-٦٠ عامًا</p></td><td style="vertical-align:top"><p dir="RTL">٠.٤ &sect;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">المسنون</p></td><td style="vertical-align:top"><p dir="RTL">أكبر من ٦٠ عامًا</p></td><td style="vertical-align:top"><p dir="RTL">٠.٣ ı</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">انهيار معاوضة القلب،</p><p dir="RTL">&nbsp; أو مرض القلب الرئوي، أو خلل في وظائف</p><p dir="RTL">&nbsp; الكبد، أو تعفن الدم المصحوب</p><p dir="RTL">&nbsp; بفشل في أعضاء متعددة،</p><p dir="RTL">&nbsp; أو الصدمة</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">٠.٢ ı</p></td></tr></tbody></table><p dir="RTL">* للوصول إلى تركيز مستهدف يبلغ ١٠ ميكروجرام/مل أمينوفيلين=ثيوفيلين/٠.٨. استخدم وزن الجسم المثالي للمرضى الذين يعانون من البدانة.</p><p dir="RTL">&dagger; قد يتطلب الأمر جرعة مبدئية أقل للمرضى الذين يتلقون عقاقير أخرى تقلل من تصفية ثيوفيلين (مثل سيميتيدين).</p><p dir="RTL">&Dagger; للوصول إلى تركيز مستهدف يبلغ ٧.٥ ميكروجرام/مل بالنسبة لحديثي الولادة المصابين بانقطاع التنفس.</p><p dir="RTL">&sect; يجب ألا تزيد عن ٩٠٠ ملجم/يوم، ما لم تعكس مستويات مصل الدم الحاجة إلى جرعة أكبر.</p><p dir="RTL">&nbsp;ı يجب ألا تزيد عن ٤٠٠ ملجم/يوم، ما لم تعكس مستويات مصل الدم الحاجة إلى جرعة أكبر.</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>الجدول ٤.&nbsp;&nbsp; التعديل النهائي للجرعة المستند إلى تركيز ثيوفيلين في مصل الدم</strong></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0" style="width:684px"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>ذروة التركيز في مصل الدم</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>تعديل الجرعة</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">أقل من ٩.٩ ميكروجرام/مل</p></td><td style="vertical-align:bottom"><p dir="RTL">إذا لم يتم التحكم في الأعراض وكانت الجرعة الحالية متحملة، فقم بزيادة معدل التسريب بنسبة ٢٥ % تقريبًا. أعد التحقق من التركيز في المصل بعد ١٢ ساعة في الأطفال و٢٤ ساعة في البالغين للتعديل الإضافي للجرعة.</p><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">١٠ إلى ١٤.٩ ميكروجرام/مل</p></td><td style="vertical-align:bottom"><p dir="RTL">إذا تم التحكم في الأعراض وكانت الجرعة الحالية متحملة، فحافظ على معدل التسريب وأعد التحقق من التركيز في المصل على فترات تبلغ ٢٤ ساعة.&para; أما إذا لم يتم التحكم في الأعراض وكانت الجرعة الحالية متحملة، فضع في اعتبارك إضافة دواء (أدوية) آخر إلى نظام العلاج.</p><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">١٥-١٩.٩ ميكروجرام/مل</p></td><td style="vertical-align:bottom"><p dir="RTL">ضع في اعتبارك تقليل معدل التسريب بنسبة ١٠ % لتوفير هامش أكبر من السلامة حتى إذا كانت الجرعة الحالية متحملة.&para;</p><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">٢٠-٢٤.٩ ميكروجرام/مل</p></td><td style="vertical-align:bottom"><p dir="RTL">قم بتقليل معدل التسريب بنسبة ٢٥ % حتى إذا لم تكن هناك آثار ضارة ظاهرة. أعد التحقق من التركيز في المصل بعد ١٢ ساعة في الأطفال و٢٤ ساعة في البالغين لتوجيه التعديل الإضافي للجرعة.</p><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">٢٥-٣٠ ميكروجرام/مل</p></td><td style="vertical-align:bottom"><p dir="RTL">قم بإيقاف التسريب لمدة ١٢ ساعة في الأطفال و٢٤ ساعة في البالغين وقم بتقليل معدل التسريب التالي بنسبة ٢٥ % على الأقل حتى إذا لم تكن هناك آثار ضارة ظاهرة. أعد التحقق من التركيز في المصل بعد ١٢ ساعة في الأطفال و٢٤ ساعة في البالغين لتوجيه التعديل الإضافي للجرعة. وإذا ظهرت أعراض على المريض، فقم بإيقاف التسريب وانظر في أمر ما إذا كانت هناك حاجة لعلاج الجرعة المفرطة أم لا (انظر &quot;توصيات الجرعة المفرطة المزمنة&quot;).</p><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">أكبر من ٣٠ ميكروجرام/مل</p></td><td style="vertical-align:bottom"><p dir="RTL">قم بإيقاف التسريب وعلاج الجرعة المفرطة وفقًا لما هو منصوص عليه (انظر &quot;توصيات الجرعة المفرطة المزمنة&quot;). وإذا تم استئناف العلاج بثيوفيلين بعد ذلك، فقم بتقليل معدل التسريب بنسبة ٥٠ % على الأقل وأعد التحقق من التركيز في مصل الدم بعد ١٢ ساعة في الأطفال و٢٤ ساعة في البالغين لتوجيه التعديل الإضافي للجرعة.</p></td></tr></tbody></table><p dir="RTL">&para;&nbsp;&nbsp;&nbsp; يستدعي الأمر تقليل الجرعة و/أو قياس تركيز ثيوفيلين في مصل الدم كلما ظهرت أي آثار ضارة أو حدثت اضطرابات فسيولوجية من شأنها تقليل تصفية ثيوفيلين (مثل، حمى مستمرة)، أو إذا تمت إضافة أو إيقاف عقار يتفاعل مع ثيوفيلين (انظر <strong><em>&quot;تحذيرات&quot;</em></strong>).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">عادةً ما تكون التفاعلات الضارة المرتبطة بثيوفيلين خفيفة عندما تكون ذروة تركيزات ثيوفيلين في مصل الدم أقل من ٢٠ ميكروجرام/مل وتتكون عادة من آثار ضارة عابرة شبيهة بآثار الكافيين مثل الغثيان، والقيء، والصداع، والأرق. إلا أنه عندما تتجاوز ذروة تركيزات ثيوفيلين في مصل الدم<br />٢٠ ميكروجرام/مل، فإن ثيوفيلين يحدث نطاقًا واسعًا من التفاعلات الضارة، بما في ذلك القيء المستمر، واضطراب ضربات القلب، والنوبات المستعصية التي قد تكون مميتة (انظر <strong><em>&quot;الجرعة المفرطة&quot;</em></strong>).</p><p dir="RTL">التفاعلات الضارة الأخرى التي تم الإبلاغ عنها عند تركيزات لثيوفيلين في مصل الدم تقل عن ٢٠ ميكروجرام/مل تتضمن الإسهال، والتهيج، والتململ، والرعاش العضلي الهيكلي البسيط، وإدرار البول العابر. في المرضى المصابين بنقص التأكسج الثانوي الناتج عن مرض الانسداد الرئوي المزمن (COPD)، تم الإبلاغ عن حالات من تسرع القلب الأذيني متعدد البؤر والرفرفة الأذينية عند تركيزات لثيوفيلين في مصل الدم تبلغ ١٥ ميكروجرام/مل أو أكبر. وكانت هناك بعض التقارير الفردية عن نوبات حدثت عند تركيزات لثيوفيلين في مصل الدم أقل من ٢٠ ميكروجرام/مل في مرضى يعانون من مرض عصبي كامن أو في مرضى مسنين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يكون حدوث النوبات في المرضى المسنين الذين تكون تركيزات ثيوفيلين في مصل الدم لديهم أقل من<br />&nbsp;٢٠ ميكروجرام/مل ناتجًا عن انخفاض الارتباط بالبروتين وهو ما يؤدي إلى وجود نسبة أكبر من التركيز الكلي لثيوفيلين في مصل الدم في صورة الشكل غير المرتبط النشط دوائيًا. كانت الخصائص الإكلينيكية للنوبات التي تم الإبلاغ عنها في المرضى الذين لديهم تركيزات ثيوفيلين في مصل الدم أقل من ٢٠ ميكروجرام/مل أخف بشكل عام من النوبات المرتبطة بزيادة تركيزات ثيوفيلين في مصل الدم الناتجة عن تناول جرعة مفرطة (أي، كانت بشكل عام عابرة وتوقفت في أغلب الحالات دون استعمال علاج مضاد للتشنجات، ولم تؤدي إلى أي ترسبات عصبية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالات نادرة، يمكن أن تسبب المنتجات التي تحتوي على أمينوفيلين تفاعلات حساسية جلدية شديدة، بما في ذلك التهاب الجلد التقشري، بعد الاستعمال الجهازي في المرضى الذين عانوا مسبقًا من حساسية نتيجة الاستعمال الموضعي لمادة تحتوي على الإيثيلين ثنائي الأمين. وفي هؤلاء المرضى، كانت نتائج اختبارات رقعة الجلد لديهم إيجابية للإيثيلين ثنائي الأمين، وهو أحد مكونات أمينوفيلين، وسلبية لثيوفيلين. وكذلك، فإن الصيادلة وغيرهم من الأفراد الذين يتعرض جلدهم بشكل متكرر لأمينوفيلين أثناء التعامل معه ماديًا يمكن أن يصابوا بالتهاب الجلد التماسي بسبب مكون الإيثيلين ثنائي الأمين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجدول ٥.</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مظاهر سمية ثيوفيلين*</strong></p><p dir="RTL"><strong>النسبة المئوية للمرضى الذين أبلغوا عن علامات أو أعراض</strong></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0" style="width:684px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p dir="RTL"><strong>الجرعة المفرطة الحادة</strong></p><p dir="RTL"><strong>(تناول جرعة فردية كبيرة)</strong></p></td><td colspan="3" style="vertical-align:top"><p dir="RTL"><strong>الجرعة المفرطة المزمنة</strong></p><p dir="RTL"><strong>(جرعات زائدة متعددة)</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>العلامات/الأعراض</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>الدراسة ١</strong></p><p dir="RTL"><strong>(العدد=١٥٧)</strong></p></td><td colspan="2" style="vertical-align:top"><p dir="RTL"><strong>الدراسة ٢</strong></p><p dir="RTL"><strong>(العدد=١٤)</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>الدراسة ١</strong></p><p dir="RTL"><strong>(العدد=٩٢)</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>الدراسة ٢</strong></p><p dir="RTL"><strong>(العدد=١٠٢)</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><u>بدون أعراض ظاهرة</u></p></td><td style="vertical-align:top"><p dir="RTL">NR**</p></td><td colspan="2" style="vertical-align:top"><p dir="RTL">٠</p></td><td style="vertical-align:top"><p dir="RTL">NR**</p></td><td style="vertical-align:top"><p dir="RTL">٦</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><u>المعدية المعوية</u></p><p dir="RTL">&nbsp;&nbsp; القيء</p><p dir="RTL">&nbsp;&nbsp; ألم البطن</p><p dir="RTL">&nbsp;&nbsp; الإسهال</p><p dir="RTL">&nbsp;&nbsp; القيء الدموي</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">٧٣</p><p dir="RTL">NR**</p><p dir="RTL">NR**</p><p dir="RTL">NR**</p></td><td colspan="2" style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">٩٣</p><p dir="RTL">٢١</p><p dir="RTL">٠</p><p dir="RTL">٠</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">٣٠</p><p dir="RTL">NR**</p><p dir="RTL">NR**</p><p dir="RTL">NR**</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">٦١</p><p dir="RTL">١٢</p><p dir="RTL">١٤</p><p dir="RTL">٢</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><u>الأيضية/الأخرى</u></p><p dir="RTL">&nbsp;&nbsp; نقص بوتاسيوم الدم</p><p dir="RTL">&nbsp;&nbsp; فرط سكر الدم</p><p dir="RTL">&nbsp;&nbsp; اضطراب توازن الأحماض/القواعد</p><p dir="RTL">&nbsp;&nbsp; انحلال الربيدات</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">٨٥</p><p dir="RTL">٩٨</p><p dir="RTL">٣٤</p><p dir="RTL">NR**</p></td><td colspan="2" style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">٧٩</p><p dir="RTL">NR**</p><p dir="RTL">٢١</p><p dir="RTL">٧</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">٤٤</p><p dir="RTL">١٨</p><p dir="RTL">٩</p><p dir="RTL">NR**</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">٤٣</p><p dir="RTL">NR**</p><p dir="RTL">٥</p><p dir="RTL">٠</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><u>القلبية الوعائية</u></p><p dir="RTL">&nbsp;&nbsp; تسرع القلب الجيبي</p><p dir="RTL">&nbsp;&nbsp; حالات أخرى</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لتسرع القلب فوق البطيني</p><p dir="RTL">&nbsp;&nbsp; ضربات البطين السابقة لأوانها</p><p dir="RTL">&nbsp;&nbsp; الرجفان الأذيني أو الرفرفة الأذينية</p><p dir="RTL">&nbsp;&nbsp; تسرع القلب الأذيني متعدد البؤر</p><p dir="RTL">&nbsp;&nbsp; اضطراب ضربات القلب البطينية المصحوبة</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعدم الاستقرار الديناميكي الدموي</p><p dir="RTL">&nbsp;&nbsp; انخفاض ضغط الدم/الصدمة</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">١٠٠</p><p dir="RTL">٢</p><p dir="RTL">&nbsp;</p><p dir="RTL">٣</p><p dir="RTL">١</p><p dir="RTL">٠</p><p dir="RTL">٧</p><p dir="RTL">&nbsp;</p><p dir="RTL">NR**</p></td><td colspan="2" style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">٨٦</p><p dir="RTL">٢١</p><p dir="RTL">&nbsp;</p><p dir="RTL">٢١</p><p dir="RTL">NR**</p><p dir="RTL">NR**</p><p dir="RTL">١٤</p><p dir="RTL">&nbsp;</p><p dir="RTL">٢١</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">١٠٠</p><p dir="RTL">١٢</p><p dir="RTL">&nbsp;</p><p dir="RTL">١٠</p><p dir="RTL">١٢</p><p dir="RTL">٢</p><p dir="RTL">٤٠</p><p dir="RTL">&nbsp;</p><p dir="RTL">NR**</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">٦٢</p><p dir="RTL">١٤</p><p dir="RTL">&nbsp;</p><p dir="RTL">١٩</p><p dir="RTL">NR**</p><p dir="RTL">NR**</p><p dir="RTL">٠</p><p dir="RTL">&nbsp;</p><p dir="RTL">٨</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><u>العصبية</u></p><p dir="RTL">&nbsp;&nbsp; التوتر</p><p dir="RTL">&nbsp;&nbsp; الرعاش</p><p dir="RTL">&nbsp;&nbsp; التوهان</p><p dir="RTL">&nbsp;&nbsp; النوبات</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">NR**</p><p dir="RTL">٣٨</p><p dir="RTL">NR**</p><p dir="RTL">٥</p></td><td colspan="2" style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">٦٤</p><p dir="RTL">٢٩</p><p dir="RTL">٧</p><p dir="RTL">١٤</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">NR**</p><p dir="RTL">١٦</p><p dir="RTL">NR**</p><p dir="RTL">١٤</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">٢١</p><p dir="RTL">١٤</p><p dir="RTL">١١</p><p dir="RTL">٥</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><u>الوفاة</u></p></td><td style="vertical-align:top"><p dir="RTL">٣</p></td><td colspan="2" style="vertical-align:top"><p dir="RTL">٢١</p></td><td style="vertical-align:top"><p dir="RTL">١٠</p></td><td style="vertical-align:top"><p dir="RTL">٤</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p dir="RTL">*&nbsp;&nbsp;&nbsp; هذه البيانات مستقاة من دراستين أجريتا على مرضى كانت تركيزات ثيوفيلين في مصل الدم لديهم<br />أكبر من ٣٠ ميكروجرام/مل. في الدراسة الأولى (الدراسة رقم ١ - شانون، دورية حوليات الطب الداخلي &quot;&rlm;Ann Intern Med&quot;&rlm; ١٩٩٣؛ ١١٩:١١٦١-٦٧)، تم جمع البيانات بشكل استباقي من ٢٤٩ حالة متتابعة لسمية ثيوفيلين تمت إحالتها إلى مركز مكافحة سموم إقليمي بغرض الاستشارة. في الدراسة الثانية (الدراسة رقم ٢ - سيسلر، الدورية الأمريكية للطب &quot;Am J Med&quot;&rlm; ١٩٩٠؛ ٨٨:٥٦٧-٧٦)، تم جمع البيانات بشكل رجعي من ١١٦ حالة لمرضى كانت تركيزات ثيوفيلين في مصل الدم لديهم أكبر<br />من ٣٠ ميكروجرام/مل من بين ٦٠٠٠ عينة دم تم الحصول عليها لقياس تركيزات ثيوفيلين في مصل الدم في ثلاثة أقسام طوارئ. الاختلافات بين معدل حدوث مظاهر سمية ثيوفيلين بين الدراستين قد تعكس اختيار العينة نتيجة لتصميم الدراسة (على سبيل المثال، في الدراسة رقم ١، أصيب ٤٨ % من المرضى بحالات تسمم حاد مقابل ١٠ % فقط في الدراسة رقم ٢) والطرق المختلفة للإبلاغ عن النتائج.</p><p dir="RTL">**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NR = لم يتم الإبلاغ عنها بطريقة قابلة للمقارنة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية:</strong><br />إذا أصبت بأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي بشأنها. يتضمن ذلك أي آثار جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية:</strong></p><p dir="RTL"><!--[if gte vml 1]><v:shapetype id="_x0000_t202"
 coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1027"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:194.1pt;margin-top:.85pt;width:268.6pt;height:63.3pt;z-index:251657216;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
 mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="window" strokeweight=".5pt">
 <v:path arrowok="t"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal dir=RTL><span dir=RTL></span><span dir=RTL></span><span
    lang=AR-EG style='font-size:12.0pt;mso-bidi-language:AR-EG'><span dir=RTL></span><span
    dir=RTL></span>-<span style='mso-spacerun:yes'>  </span>المركز الوطني
    للتيقظ الدوائي:<o:p></o:p></span></p>
    <p class=MsoListParagraph dir=RTL style='margin-top:0in;margin-right:.5in;
    margin-bottom:0in;margin-left:-.1pt;margin-bottom:.0001pt;text-align:justify;
    mso-list:l1 level1 lfo2;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='font-size:12.0pt;font-family:"Courier New";mso-fareast-font-family:
    "Courier New";mso-bidi-language:AR-EG'><span style='mso-list:Ignore'>o<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
    dir=RTL></span><span lang=AR-EG style='font-size:12.0pt;mso-bidi-language:
    AR-EG'>مركز </span><span lang=AR-SA style='mso-bidi-language:AR-SA'>الاتصال</span><span
    lang=AR-EG style='font-size:12.0pt;mso-bidi-language:AR-EG'> الموحد: </span><span
    lang=FA style='mso-ascii-font-family:Arial;mso-hansi-font-family:Arial;
    color:black;background:white;mso-bidi-language:FA'>۱۹۹۹۹</span><span
    lang=FA style='font-size:12.0pt;mso-bidi-language:AR-EG'> </span><span
    dir=LTR style='font-size:12.0pt;mso-bidi-language:AR-EG'><o:p></o:p></span></p>
    <p class=MsoListParagraph dir=RTL style='margin-top:0in;margin-right:.5in;
    margin-bottom:0in;margin-left:-.1pt;margin-bottom:.0001pt;text-align:justify;
    mso-list:l1 level1 lfo2;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='font-size:12.0pt;font-family:"Courier New";mso-fareast-font-family:
    "Courier New";mso-bidi-language:AR-EG'><span style='mso-list:Ignore'>o<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
    dir=RTL></span><span lang=AR-EG style='font-size:12.0pt;mso-bidi-language:
    AR-EG'>البريد الالكتروني: </span><span dir=LTR style='font-size:12.0pt;
    mso-bidi-language:AR-EG'>npc.drug@sfda.gov.sa<o:p></o:p></span></p>
    <p class=MsoListParagraph dir=RTL style='margin-top:0in;margin-right:.5in;
    margin-bottom:0in;margin-left:-.1pt;margin-bottom:.0001pt;text-align:justify;
    mso-list:l1 level1 lfo2;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='font-size:12.0pt;font-family:"Courier New";mso-fareast-font-family:
    "Courier New";mso-bidi-language:AR-EG'><span style='mso-list:Ignore'>o<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
    dir=RTL></span><span lang=AR-EG style='font-size:12.0pt;mso-bidi-language:
    AR-EG'>الموقع الالكتروني: </span><span dir=LTR style='font-size:12.0pt;
    mso-bidi-language:AR-EG'>https://ade.sfda.gov.sa<o:p></o:p></span></p>
    <p class=MsoNormal dir=RTL style='margin-top:0in;margin-right:.25in;
    margin-bottom:12.0pt;margin-left:0in;mso-add-space:auto;line-height:150%'><span
    dir=RTL></span><span dir=RTL></span><span style='font-size:12.0pt;
    line-height:150%;mso-bidi-language:AR-EG'><span dir=RTL></span><span
    dir=RTL></span><span style='mso-spacerun:yes'> </span><span lang=AR-EG><o:p></o:p></span></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><p dir="RTL">المركز الوطني للتيقظ الدوائي:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال الموحد: ۱۹۹۹۹</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الالكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الالكتروني: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><!--[if gte vml 1]><v:shape
 id="Text_x0020_Box_x0020_3" o:spid="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
 left:0;text-align:left;margin-left:195.7pt;margin-top:7.25pt;width:269.4pt;
 height:24.3pt;z-index:251658240;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:margin;v-text-anchor:top'
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="window" strokeweight=".5pt">
 <v:path arrowok="t"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal dir=RTL><span dir=RTL></span><span dir=RTL></span><span
    lang=AR-EG style='font-size:12.0pt;mso-bidi-language:AR-EG'><span dir=RTL></span><span
    dir=RTL></span>-<span style='mso-spacerun:yes'>  </span>الرجاء الاتصال
    بالمؤسسات والهيئات الوطنية في كل دولة.<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left" style="width:384.2px"><tbody><tr><td style="width:1px">&nbsp;</td></tr><tr><td style="width:1px">&nbsp;</td><td style="width:385.8px"><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى:</strong></p><p>-&nbsp; الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">فترة الصلاحية: ١٨ شهرا.</p></td></tr></tbody></table><p dir="RTL">خزنه في درجة حرارة أقل من ٢٥ درجة مئوية.</p><p dir="RTL">احفظه بعيدًا عن الضوء. خزنه في عبوته الكرتونية حتى حلول وقت استخدامه.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">٢٥ ملجم/مل ثنائي هيدرات أمينوفيلين</p><p dir="RTL">(بما يعادل ١٩.٧ ملجم/مل ثيوفيلين لا مائي)</p><p dir="RTL">إيثيلين ثنائي الأمين، نيتروجين، ماء مخصص للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">يتم توفير حقن أمينوفيلين ٢٥ ملجم/مل، وفقًا لدستور الأدوية الأمريكي، في حاويات ذات جرعات فردية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>مالك تصريح التسويق</strong></p><p>&nbsp;</p><p>Hospira, Inc., Lake Forest, IL 60045 USA، الولايات المتحدة الأمريكية</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>الجهة المُصنعة</strong></p><p>&nbsp;</p><p>Hospira INC, Rocky Mount, United states، الولايات المتحدة الأمريكية.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مارس/آذار ٢٠١٨
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aminophylline 25 mg/ml solution for injection				
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aminophylline Injection, USP is a sterile, nonpyrogenic solution of aminophylline in water for injection. Aminophylline (dihydrate) is approximately 79% of anhydrous theophylline by weight. Aminophylline Injection is administered by slow intravenous injection or diluted and administered by intravenous infusion.
The solution contains no bacteriostat or antimicrobial agent and is intended for use only as a single-dose injection. When smaller doses are required the unused portion should be discarded.

Aminophylline is a 2:1 complex of theophylline and ethylenediamine. Theophylline is structurally classified as a methylxanthine. Aminophylline occurs as a white or slightly yellowish granule or powder, with a slight ammoniacal odor. Aminophylline has the chemical name 1H Purine-2, 6-dione, 3,7-dihydro-1,3-dimethyl-, compound with 1,2-ethanediamine (2:1). The structural formula of aminophylline (dihydrate) is as follows:

The molecular formula of aminophylline dihydrate is C16H24N10O4 • 2(H2O) with a molecular weight of 456.46.

Aminophylline Injection, USP contains aminophylline (calculated as the dihydrate) 25 mg/mL (equivalent to 19.7 mg/mL anhydrous theophylline) prepared with the aid of ethylenediamine. The solution may contain an excess of ethylenediamine for pH adjustment. pH is 8.8 (8.6 to 9.0). The osmolar concentration is 0.17 mOsmol/mL (calc.).

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection supplied in single-dose containers as Fliptop Vial 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Intravenous theophylline is indicated as an adjunct to inhaled beta-2 selective agonists and systemically administered corticosteroids for the treatment of acute exacerbations of the symptoms and reversible airflow obstruction associated with asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General Considerations:</p><p>The steady-state serum theophylline concentration is a function of the infusion rate and the rate of theophylline clearance in the individual patient. Because of marked individual differences in the rate of theophylline clearance, the dose required to achieve a serum theophylline concentration in the<br />10-20 mcg/mL range varies fourfold among otherwise similar patients in the absence of factors known to alter theophylline clearance. For a given population there is no single theophylline dose that will provide both safe and effective serum concentrations for all patients. Administration of the median theophylline dose required to achieve a therapeutic serum theophylline concentration in a given population may result in either sub-therapeutic or potentially toxic serum theophylline concentrations in individual patients. <strong><u>The dose of theophylline must be individualized on the basis of serum theophylline concentration measurements in order to achieve a dose that will provide maximum potential benefit with minimal risk of adverse effects.</u></strong></p><p>&nbsp;</p><p>When theophylline is used as an acute bronchodilator, the goal of obtaining a therapeutic serum concentration is best accomplished with an intravenous loading dose. Because of rapid distribution into body fluids, the serum concentration (C) obtained from an initial loading dose (LD) is related primarily to the volume of distribution (V), the apparent space into which the drug diffuses:</p><p>C = LD/V</p><p>&nbsp;</p><p>If a mean volume of distribution of about 0.5 L/kg is assumed (actual range is 0.3 to 0.7 L/kg), each mg/kg (ideal body weight) of theophylline administered as a loading dose over 30 minutes results in an average 2 mcg/mL increase in serum theophylline concentration. Therefore, in a patient who has received no theophylline in the previous 24 hours, a loading dose of intravenous theophylline of 4.6 mg/kg<br />(5.7 mg/kg as aminophylline), calculated on the basis of ideal body weight and administered over 30 minutes, on average, will produce a maximum post-distribution serum concentration of 10 mcg/mL with a range of 6-16 mcg/mL. When a loading dose becomes necessary in the patient who has already received theophylline, estimation of the serum concentration based upon the history is unreliable, and an immediate serum level determination is indicated. The loading dose can then be determined as follows:</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>D = (Desired C - Measured C) (V)</p><p>where D is the loading dose, C is the serum theophylline concentration, and V is the volume of distribution. The mean volume of distribution can be assumed to be 0.5 L/kg and the desired serum concentration should be conservative (e.g., 10 mcg/mL) to allow for the variability in the volume of distribution. <strong><u>A loading dose should not be given before obtaining a serum theophylline concentration if the patient has received any theophylline in the previous 24 hours.</u></strong></p><p>&nbsp;</p><p>A serum concentration obtained 30 minutes after an intravenous loading dose, when distribution is complete, can be used to assess the need for and size of subsequent loading doses, if clinically indicated, and for guidance of continuing therapy. Once a serum concentration of 10 to 15 mcg/mL has been achieved with the use of a loading dose(s), a constant intravenous infusion is started. The rate of administration is based upon mean pharmacokinetic parameters for the population and calculated to achieve a target serum concentration of 10 mcg/mL (see <strong>Table 1</strong>). For example, in non-smoking adults, initiation of a constant intravenous theophylline infusion of 0.4&nbsp;mg/kg/hr (0.5 mg/kg/hr as aminophylline) at the completion of the loading dose, on average, will result in a steady-state concentration of 10 mcg/mL with a range of 7-26 mcg/mL. The mean and range of steady-state serum concentrations are similar when the average child (age 1 to 9 years) is given a loading dose of 4.6 mg/kg theophylline (5.7 mg/kg as aminophylline) followed by a constant intravenous infusion of 0.8 mg/kg/hr (1.0 mg/kg/hr as aminophylline). Since there is large interpatient variability in theophylline clearance, serum concentrations will rise or fall when the patient&rsquo;s clearance is significantly different from the mean population value used to calculate the initial infusion rate. Therefore, a second serum concentration should be obtained one expected half-life after starting the constant infusion (e.g., approximately 4 hours for children age 1 to 9 and 8&nbsp;hours for nonsmoking adults; See <strong>Table 6</strong> for the expected half-life in additional patient populations) to determine if the concentration is accumulating or declining from the post loading dose level. If the level is declining as a result of a higher than average clearance, an additional loading dose can be administered and/or the infusion rate increased. In contrast, if the second sample demonstrates a higher level, accumulation of the drug can be assumed, and the infusion rate should be decreased before the concentration exceeds 20 mcg/mL. An additional sample is obtained 12 to 24 hours later to determine if further adjustments are required and then at 24-hour intervals to adjust for changes, if they occur. This empiric method, based upon mean pharmacokinetic parameters, will prevent large fluctuations in serum concentration during the most critical period of the patient&rsquo;s course.</p><p>&nbsp;</p><p>In patients with cor pulmonale, cardiac decompensation, or liver dysfunction, or in those taking drugs that markedly reduce theophylline clearance (e.g., cimetidine), the initial theophylline infusion rate should not exceed 17 mg/hr (21 mg/hr as aminophylline) unless serum concentrations can be monitored at 24-hour intervals. In these patients, 5 days may be required before steady-state is reached.</p><p>Theophylline distributes poorly into body fat, therefore, mg/kg dose should be calculated on the basis of ideal body weight.</p><p><strong>&nbsp;</strong></p><p><strong>Table 1</strong> contains initial theophylline infusion rates following an appropriate loading dose recommended for patients in various age groups and clinical circumstances. <strong>Table 2</strong> contains recommendations for final theophylline dosage adjustment based upon serum theophylline concentrations. <strong><u>Application of these general dosing recommendations to individual patients must take into account the unique clinical characteristics of each patient. In general, these recommendations should serve as the upper limit for dosage adjustments in order to decrease the risk of potentially serious adverse events associated with unexpected large increases in serum theophylline concentration.</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p><strong>Table 1.&nbsp;&nbsp; Initial Theophylline Infusion Rates Following an Appropriate Loading Dose.</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:679px"><tbody><tr><td style="vertical-align:top"><p><strong>Patient population</strong></p></td><td style="vertical-align:top"><p><strong>Age</strong></p></td><td style="vertical-align:top"><p><strong>Theophylline infusion rate (mg/kg/hr)*&dagger;&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Neonates</p></td><td style="vertical-align:top"><p>Postnatal age up to 24 days</p><p>Postnatal age beyond 24 days</p></td><td style="vertical-align:top"><p>1 mg/kg q12h/&Dagger;</p><p>1.5 mg/kg q12h/&Dagger;</p></td></tr><tr><td style="vertical-align:top"><p>Infants</p></td><td style="vertical-align:top"><p>6-52 weeks old</p></td><td style="vertical-align:top"><p>mg/kg/hr= (0.008)(age in weeks) + 0.21</p></td></tr><tr><td style="vertical-align:top"><p>Young children</p></td><td style="vertical-align:top"><p>1-9 years</p></td><td style="vertical-align:top"><p>0.8</p></td></tr><tr><td style="vertical-align:top"><p>Older children</p></td><td style="vertical-align:top"><p>9-12 years</p></td><td style="vertical-align:top"><p>0.7</p></td></tr><tr><td style="vertical-align:top"><p>Adolescents</p><p>&nbsp; (cigarette or marijuana</p><p>&nbsp; smokers)</p></td><td style="vertical-align:top"><p>12-16 years</p></td><td style="vertical-align:top"><p>0.7</p></td></tr><tr><td style="vertical-align:top"><p>Adolescents (nonsmokers)</p></td><td style="vertical-align:top"><p>12-16 years</p></td><td style="vertical-align:top"><p>0.5 &sect;</p></td></tr><tr><td style="vertical-align:top"><p>Adults</p><p>&nbsp; (otherwise healthy</p><p>&nbsp; nonsmokers)</p></td><td style="vertical-align:top"><p>16-60 years</p></td><td style="vertical-align:top"><p>0.4 &sect;</p></td></tr><tr><td style="vertical-align:top"><p>Elderly</p></td><td style="vertical-align:top"><p>&gt;60 years</p></td><td style="vertical-align:top"><p>0.3 ı</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac decompensation,</p><p>&nbsp; cor pulmonale, liver</p><p>&nbsp; dysfunction, sepsis with</p><p>&nbsp; multiorgan failure,</p><p>&nbsp; or shock</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>0.2 ı</p></td></tr></tbody></table><p>*&nbsp; To achieve a target concentration of 10 mcg/mL Aminophylline=theophylline/0.8. Use ideal body weight for obese patients.</p><p>&dagger;&nbsp; Lower initial dosage may be required for patients receiving other drugs that decrease theophylline clearance (e.g., cimetidine).</p><p>&Dagger;&nbsp; To achieve a target concentration of 7.5 mcg/mL for neonatal apnea.</p><p>&sect;&nbsp; Not to exceed 900 mg/day, unless serum levels indicate the need for a larger dose.</p><p>&nbsp;ı&nbsp; Not to exceed 400 mg/day, unless serum levels indicate the need for a larger dose.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Table 2.&nbsp;&nbsp; Final Dosage Adjustment Guided by Serum Theophylline Concentration</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:684px"><tbody><tr><td style="vertical-align:top"><p><strong>Peak Serum Concentration</strong></p></td><td style="vertical-align:top"><p><strong>Dosage Adjustment</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&lt;9.9 mcg/mL</p></td><td style="vertical-align:bottom"><p>If symptoms are not controlled and current dosage is tolerated, increase infusion rate about 25%. Recheck serum concentration after 12 hours in children and 24 hours in adults for further dosage adjustment.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>10 to 14.9 mcg/mL</p></td><td style="vertical-align:bottom"><p>If symptoms are controlled and current dosage is tolerated, maintain infusion rate and recheck serum concentration at 24 hour intervals.&para; If symptoms are not controlled and current dosage is tolerated consider adding additional medication(s) to treatment regimen.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>15-19.9 mcg/mL</p></td><td style="vertical-align:bottom"><p>Consider 10% decrease in infusion rate to provide greater margin of safety even if current dosage is tolerated.&para;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>20-24.9 mcg/mL</p></td><td style="vertical-align:bottom"><p>Decrease infusion rate by 25% even if no adverse effects are present. Recheck serum concentration after 12 hours in children and 24 hours in adults to guide further dosage adjustment.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>25-30 mcg/mL</p></td><td style="vertical-align:bottom"><p>Stop infusion for 12 hours in children and 24 hours in adults and decrease subsequent infusion rate at least 25% even if no adverse effects are present. Recheck serum concentration after 12 hours in children and 24 hours in adults to guide further dosage adjustment. If symptomatic, stop infusion and consider whether overdose treatment is indicated (see recommendations for chronic overdosage).</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;30 mcg/mL</p></td><td style="vertical-align:bottom"><p>Stop the infusion and treat overdose as indicated (see recommendations for chronic overdosage). If theophylline is subsequently resumed, decrease infusion rate by at least 50% and recheck serum concentration after 12 hours in children and 24 hours in adults to guide further dosage adjustment.</p></td></tr></tbody></table><p>&para;&nbsp;&nbsp;&nbsp; Dose reduction and/or serum theophylline concentration measurement is indicated whenever adverse effects are present, physiologic abnormalities that can reduce theophylline clearance occur (e.g., sustained fever), or a drug that interacts with theophylline is added or discontinued (see <strong><em>WARNINGS</em></strong>).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aminophylline is contraindicated in patients with a history of hypersensitivity to theophylline or other components in the product including ethylenediamine.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>WARNINGS</em></strong></p><p><strong>&nbsp;</strong></p><p><strong>Concurrent Illness:</strong></p><p>Theophylline should be used with extreme caution in patients with the following clinical conditions due to the increased risk of exacerbation of the concurrent condition:</p><p>Active peptic ulcer disease</p><p>Seizure disorders</p><p>Cardiac arrhythmias (not including bradyarrhythmias)</p><p><strong>&nbsp;</strong></p><p><strong>Conditions That Reduce Theophylline Clearance:</strong></p><p>There are several readily identifiable causes of reduced theophylline clearance. <strong><em><u>If the infusion rate is not appropriately reduced in the presence of these risk factors, severe and potentially fatal theophylline toxicity can occur.</u></em></strong> Careful consideration must be given to the benefits and risks of theophylline use and the need for more intensive monitoring of serum theophylline concentrations in patients with the following risk factors:</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Age</strong></p><p>Neonates (term and premature)</p><p>Children &lt;1 year</p><p>Elderly (&gt;60 years)</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Concurrent Diseases</strong></p><p>Acute pulmonary edema</p><p>Congestive heart failure</p><p>Cor pulmonale</p><p>Fever; &ge;102&deg; for 24 hours or more; or lesser temperature elevations for longer periods</p><p>Hypothyroidism</p><p>Liver disease; cirrhosis, acute hepatitis</p><p>Reduced renal function in infants &lt;3 months of age</p><p>Sepsis with multi-organ failure</p><p>Shock</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cessation of Smoking</strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drug Interactions</strong></p><p>Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See <strong><em>PRECAUTIONS</em></strong>, <strong>Drug Interactions</strong>, <strong>Table 3</strong>.)</p><p><strong>&nbsp;</strong></p><p><strong>When Signs or Symptoms of Theophylline Toxicity Are Present:</strong></p><p><strong><u>Whenever a patient receiving theophylline develops nausea or vomiting, particularly repetitive vomiting, or other signs or symptoms consistent with theophylline toxicity (even if another cause may be suspected), the intravenous infusion should be stopped and a serum theophylline concentration measured immediately.</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Dosage Increases</u></strong></p><p>Increases in the dose of intravenous theophylline should not be made in response to an acute exacerbation of symptoms unless the steady-state serum theophylline concentration is &lt;10&nbsp;mcg/mL.</p><p>&nbsp;</p><p>As the rate of theophylline clearance may be dose-dependent (i.e., steady-state serum concentrations may increase disproportionately to the increase in dose), an increase in dose based upon a sub-therapeutic serum concentration measurement should be conservative. In general, limiting infusion rate increases to about 25% of the previous infusion rate will reduce the risk of unintended excessive increases in serum theophylline concentration (see <strong><em>DOSAGE AND ADMINISTRATION</em></strong>, <strong>TABLE 2</strong>).</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>PRECAUTIONS</em></strong></p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>General</u></strong></p><p>Careful consideration of the various interacting drugs and physiologic conditions that can alter theophylline clearance and require dosage adjustment should occur prior to initiation of theophylline therapy and prior to increases in theophylline dose (see <strong><em>WARNINGS</em></strong>).</p><p><strong>&nbsp;</strong></p><p><strong>Monitoring Serum Theophylline Concentrations:</strong></p><p>Serum theophylline concentration measurements are readily available and should be used to determine whether the dosage is appropriate. Specifically, the serum theophylline concentration should be measured as follows:</p><p>1.&nbsp;&nbsp; Before making a dose increase to determine whether the serum concentration is sub-therapeutic in a patient who continues to be symptomatic.</p><p>2.&nbsp;&nbsp; Whenever signs or symptoms of theophylline toxicity are present.</p><p>3.&nbsp;&nbsp; Whenever there is a new illness, worsening of an existing concurrent illness or a change in the patient&rsquo;s treatment regimen that may alter theophylline clearance (e.g., fever &gt;102&deg;F sustained for &ge;24 hours, hepatitis, or drugs listed in <strong>Table</strong> <strong>3</strong> are added or discontinued).</p><p>&nbsp;</p><p>In patients who have received no theophylline in the previous 24 hours, a serum concentration should be measured 30 minutes after completion of the intravenous loading dose to determine whether the serum concentration is &lt;10 mcg/mL indicating the need for an additional loading dose or &gt;20 mcg/mL indicating the need to delay starting the constant intravenous infusion. Once the infusion is begun, a second measurement should be obtained after one expected half-life (e.g., approximately 4&nbsp;hours in children 1 to 9 years and 8 hours in non-smoking adults; See <strong>Table 6</strong> for the expected half-life in additional patient populations). The second measurement should be compared to the first to determine the direction in which the serum concentration has changed. The infusion rate can then be adjusted before steady state is reached in an attempt to prevent an excessive or sub-therapeutic theophylline concentration from being achieved.</p><p>&nbsp;</p><p>If a patient has received theophylline in the previous 24 hours, the serum concentration should be measured before administering an intravenous loading dose to make sure that it is safe to do so. If a loading dose is not indicated (i.e., the serum theophylline concentration is &ge;10 mcg/mL), a second measurement should be obtained as above at the appropriate time after starting the intravenous infusion. If, on the other hand, a loading dose is indicated (See <strong><em>DOSAGE AND ADMINISTRATION</em></strong> for guidance on selection of the appropriate loading dose), a second blood sample should be obtained after the loading dose and a third sample should be obtained one expected half-life after starting the constant infusion to determine the direction in which the serum concentration has changed.</p><p>&nbsp;</p><p>Once the above procedures related to initiation of intravenous theophylline infusion have been completed, subsequent serum samples for determination of theophylline concentration should be obtained at 24-hour intervals for the duration of the infusion. The theophylline infusion rate should be increased or decreased as appropriate based on the serum theophylline levels.</p><p>&nbsp;</p><p>When signs or symptoms of theophylline toxicity are present, the intravenous infusion should be stopped and a serum sample for theophylline concentration should be obtained as soon as possible, analyzed immediately, and the result reported to the clinician without delay. In patients in whom decreased serum protein binding is suspected (e.g., cirrhosis, women during the third trimester of pregnancy), the concentration of unbound theophylline should be measured and the dosage adjusted to achieve an unbound concentration of 6-12 mcg/mL.</p><p>&nbsp;</p><p>Saliva concentrations of theophylline cannot be used reliably to adjust dosage without special techniques.</p><p><br /><strong>Effects on Laboratory Tests:</strong></p><p>As a result of its pharmacological effects, theophylline at serum concentrations within the 10&nbsp;‑&nbsp;20&nbsp;mcg/mL range modestly increases plasma glucose (from a mean of 88 mg% to 98 mg%), uric acid (from a mean of 4 mg/dl to 6 mg/dl), free fatty acids (from a mean of 451 &micro;Eq/L to 800&nbsp;&micro;Eq/L), total cholesterol (from a mean of 140 vs 160 mg/dl), HDL (from a mean of 36 to 50&nbsp;mg/dl), HDL/LDL ratio (from a mean of 0.5 to 0.7), and urinary free cortisol excretion (from a mean of 44 to 63 mcg/24 hr). Theophylline at serum concentrations within the 10 - 20 mcg/mL range may also transiently decrease serum concentrations of triiodothyronine (144 before, 131 after one week and 142 ng/dl after 4 weeks of theophylline). The clinical importance of these changes should be weighed against the potential therapeutic benefit of theophylline in individual patients.</p><p>&nbsp;</p><p><strong>Pediatric Use:</strong></p><p>Theophylline is safe and effective for the approved indications in pediatric patients (see <strong><em>INDICATIONS AND USAGE</em></strong>). The constant infusion rate of intravenous theophylline must be selected with caution in pediatric patients since the rate of theophylline clearance is highly variable across the age range of neonates to adolescents (see <strong><em>CLINICAL PHARMACOLOGY</em></strong>, <strong>Table 6</strong>, <strong><em>WARNINGS</em></strong>, and <strong><em>DOSAGE AND ADMINISTRATION</em></strong>, <strong>Table 1</strong>). Due to the immaturity of theophylline metabolic pathways in pediatric patients under the age of one year, particular attention to dosage selection and frequent monitoring of serum theophylline concentrations are required when theophylline is prescribed to pediatric patients in this age group.</p><p><strong>&nbsp;</strong></p><p><strong>Geriatric Use:</strong></p><p>Elderly patients are at significantly greater risk of experiencing serious toxicity from theophylline than younger patients due to pharmacokinetic and pharmacodynamic changes associated with aging. Theophylline clearance is reduced in patients greater than 60 years of age, resulting in increased serum theophylline concentrations in response to a given theophylline infusion rate. Protein binding may be decreased in the elderly resulting in a larger proportion of the total serum theophylline concentration in the pharmacologically active unbound form. Elderly patients also appear to be more sensitive to the toxic effects of theophylline after chronic overdosage than younger patients. For these reasons, the maximum infusion rate of theophylline in patients greater than 60 years of age ordinarily should not exceed<br />17 mg/hr (21 mg/hr as aminophylline) unless the patient continues to be symptomatic and the peak steady state serum theophylline concentration is &lt;10 mcg/mL (see <strong><em>DOSAGE AND ADMINISTRATION</em></strong>). Theophylline infusion rates greater than 17 mg/hr (21 mg/hr as aminophylline) should be prescribed with caution in elderly patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Theophylline interacts with a wide variety of drugs. The interaction may be pharmacodynamic, i.e., alterations in the therapeutic response to theophylline or another drug or occurrence of adverse effects without a change in serum theophylline concentration. More frequently, however, the interaction is pharmacokinetic, i.e., the rate of theophylline clearance is altered by another drug resulting in increased or decreased serum theophylline concentrations. Theophylline only rarely alters the pharmacokinetics of other drugs.</p><p>&nbsp;</p><p>The drugs listed in <strong>Table 3</strong> have the potential to produce clinically significant pharmacodynamic or pharmacokinetic interactions with theophylline. The information in the &ldquo;Effect&rdquo; column of <strong>Table 3</strong> assumes that the interacting drug is being added to a steady-state theophylline regimen. If theophylline is being initiated in a patient who is already taking a drug that inhibits theophylline clearance (e.g., cimetidine, erythromycin), the dose of theophylline required to achieve a therapeutic serum theophylline concentration will be smaller. Conversely, if theophylline is being initiated in a patient who is already taking a drug that enhances theophylline clearance (e.g., rifampin), the dose of theophylline required to achieve a therapeutic serum theophylline concentration will be larger. Discontinuation of a concomitant drug that increases theophylline clearance will result in accumulation of theophylline to potentially toxic levels, unless the theophylline dose is appropriately reduced. Discontinuation of a concomitant drug that inhibits theophylline clearance will result in decreased serum theophylline concentrations, unless the theophylline dose is appropriately increased.</p><p>&nbsp;</p><p>The drugs listed in <strong>Table 4</strong> have either been documented not to interact with theophylline or do not produce a clinically significant interaction (i.e., &lt;15% change in theophylline clearance).</p><p>&nbsp;</p><p>The listing of drugs in <strong>Tables 3 and 4</strong> are current as of September 1, 1995. New interactions are continuously being reported for theophylline, especially with new chemical entities. <strong><u>The clinician should not assume that a drug does not interact with theophylline if it is not listed in Table 3.</u></strong> Before addition of a newly available drug in a patient receiving theophylline, the package insert of the new drug and/or the medical literature should be consulted to determine if an interaction between the new drug and theophylline has been reported.</p><p>&nbsp;</p><p><strong>Table 3.&nbsp;&nbsp; Clinically Significant Drug Interactions With Theophylline*</strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:bottom"><p><strong>Drug</strong></p></td><td style="vertical-align:bottom"><p><strong>Type Of Interaction</strong></p></td><td style="vertical-align:bottom"><p><strong>Effect**</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Adenosine</p></td><td style="vertical-align:top"><p>Theophylline blocks adenosine</p><p>receptors.</p></td><td style="vertical-align:top"><p>Higher doses of adenosine may be required to achieve desired effect.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Alcohol</p></td><td style="vertical-align:top"><p>A single large dose of alcohol</p><p>(3 mL/kg of whiskey) decreases</p><p>theophylline clearance for up to 24 hours.</p></td><td style="vertical-align:top"><p>30% increase</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Allopurinol</p></td><td style="vertical-align:top"><p>Decreases theophylline clearance at allopurinol doses &ge;600 mg/day.</p></td><td style="vertical-align:top"><p>25% increase</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Aminoglutethimide</p></td><td style="vertical-align:top"><p>Increases theophylline clearance by</p><p>induction of microsomal enzyme activity.</p></td><td style="vertical-align:top"><p>25% decrease</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Carbamazepine</p></td><td style="vertical-align:top"><p>Similar to aminoglutethimide.</p></td><td style="vertical-align:top"><p>30% decrease</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cimetidine</p></td><td style="vertical-align:top"><p>Decreases theophylline clearance by inhibiting cytochrome P450 1A2.</p></td><td style="vertical-align:top"><p>70% increase</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ciprofloxacin</p></td><td style="vertical-align:top"><p>Similar to cimetidine.&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>40% increase</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Clarithromycin</p></td><td style="vertical-align:top"><p>Similar to erythromycin.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>25% increase</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Diazepam</p></td><td style="vertical-align:top"><p>Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors.</p></td><td style="vertical-align:top"><p>Larger diazepam doses may be</p><p>required to produce desired level of sedation. Discontinuation of theophylline without reduction of diazepam dose may result in respiratory depression.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Disulfiram</p></td><td style="vertical-align:top"><p>Decreases theophylline clearance by inhibiting hydroxylation and demethylation.</p></td><td style="vertical-align:top"><p>50% increase</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Enoxacin</p></td><td style="vertical-align:top"><p>Similar to cimetidine.&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>300% increase</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ephedrine</p></td><td style="vertical-align:top"><p>Synergistic CNS effects.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>Increased frequency of nausea,</p><p>nervousness, and insomnia.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Erythromycin</p></td><td style="vertical-align:top"><p>Erythromycin metabolite decreases theophylline clearance by inhibiting</p><p>cytochrome P450 3A3.</p></td><td style="vertical-align:top"><p>35% increase. Erythromycin</p><p>steady-state serum concentrations decrease by a similar amount.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Estrogen</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Estrogen containing oral contraceptives decrease theophylline clearance in a dose-dependent fashion.</p><p>The effect of progesterone on theophylline clearance is unknown.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>30% increase</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Flurazepam</p></td><td style="vertical-align:top"><p>Similar to diazepam.</p></td><td style="vertical-align:top"><p>Similar to diazepam.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table 3.&nbsp;&nbsp; Clinically Significant Drug Interactions With Theophylline* (continued)</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:bottom"><p><strong>Drug</strong></p></td><td style="vertical-align:bottom"><p><strong>Type Of Interaction</strong></p></td><td style="vertical-align:bottom"><p><strong>Effect**</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Fluvoxamine</p></td><td style="vertical-align:top"><p>Similar to cimetidine.</p></td><td style="vertical-align:top"><p>Similar to cimetidine.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Halothane</p></td><td style="vertical-align:top"><p>Halothane sensitizes the myocardium</p><p>to catecholamines, theophylline</p><p>increases release of endogenous</p><p>catecholamines.</p></td><td style="vertical-align:top"><p>Increased risk of ventricular</p><p>arrhythmias.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Interferon, human</p><p>recombinant alpha-A</p></td><td style="vertical-align:top"><p>Decreases theophylline clearance.</p></td><td style="vertical-align:top"><p>100% increase</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Isoproterenol (I.V.)</p></td><td style="vertical-align:top"><p>Increases theophylline clearance.</p></td><td style="vertical-align:top"><p>20% decrease</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ketamine</p></td><td style="vertical-align:top"><p>Pharmacologic</p></td><td style="vertical-align:top"><p>May lower theophylline</p><p>seizure threshold.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Lithium</p></td><td style="vertical-align:top"><p>Theophylline increases renal lithium clearance.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>Lithium dose required to achieve a therapeutic serum concentration increased an average of 60%.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Lorazepam</p></td><td style="vertical-align:top"><p>Similar to diazepam.</p></td><td style="vertical-align:top"><p>Similar to diazepam.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Methotrexate (MTX)</p></td><td style="vertical-align:top"><p>Decreases theophylline clearance.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>20% increase after low dose MTX, higher dose MTX may have a greater effect.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Mexiletine</p></td><td style="vertical-align:top"><p>Similar to disulfiram.</p></td><td style="vertical-align:top"><p>80% increase</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Midazolam</p></td><td style="vertical-align:top"><p>Similar to diazepam.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>Similar to diazepam.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Moricizine</p></td><td style="vertical-align:top"><p>Increases theophylline clearance.</p></td><td style="vertical-align:top"><p>25% decrease</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pancuronium</p></td><td style="vertical-align:top"><p>Theophylline may antagonize</p><p>nondepolarizing neuromuscular blocking effects; possibly due to phosphodiesterase inhibition.</p></td><td style="vertical-align:top"><p>Larger dose of pancuronium may be required to achieve neuromuscular blockade.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pentoxifylline</p></td><td style="vertical-align:top"><p>Decreases theophylline clearance.</p></td><td style="vertical-align:top"><p>30% increase</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Phenobarbital (PB)</p></td><td style="vertical-align:top"><p>Similar to aminoglutethimide.</p></td><td style="vertical-align:top"><p>25% decrease after two weeks of concurrent Phenobarbital.</p></td></tr><tr><td style="vertical-align:top"><p>Phenytoin</p></td><td style="vertical-align:top"><p>Phenytoin increases theophylline</p><p>clearance by increasing microsomal</p><p>enzyme activity. Theophylline decreases</p><p>phenytoin absorption.</p></td><td style="vertical-align:top"><p>Serum theophylline and phenytoin concentrations decrease about 40%.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Propafenone</p></td><td style="vertical-align:top"><p>Decreases theophylline clearance and</p><p>pharmacologic interaction.</p></td><td style="vertical-align:top"><p>40% increase. Beta-2 blocking</p><p>effect may decrease efficacy of theophylline.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Table 3.&nbsp;&nbsp; Clinically Significant Drug Interactions With Theophylline* (continued)</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Drug</strong></p></td><td style="vertical-align:top"><p><strong>Type Of Interaction</strong></p></td><td style="vertical-align:top"><p><strong>Effect**</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Propranolol</p></td><td style="vertical-align:top"><p>Similar to cimetidine and pharmacologic interaction.</p></td><td style="vertical-align:top"><p>100% increase. Beta-2 blocking</p><p>effect may decrease efficacy of theophylline.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rifampin</p></td><td style="vertical-align:top"><p>Increases theophylline clearance by</p><p>increasing cytochrome P450 1A2 and 3A3 activity.</p></td><td style="vertical-align:top"><p>20 - 40% decrease</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Sulfinpyrazone</p></td><td style="vertical-align:top"><p>Increases theophylline clearance by</p><p>increasing demethylation and hydroxylation. Decreases renal clearance of theophylline.</p></td><td style="vertical-align:top"><p>20% decrease</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Tacrine</p></td><td style="vertical-align:top"><p>Similar to cimetidine, also increases renal clearance of theophylline.</p></td><td style="vertical-align:top"><p>90% increase</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Thiabendazole</p></td><td style="vertical-align:top"><p>Decreases theophylline clearance.</p></td><td style="vertical-align:top"><p>190% increase</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ticlopidine</p></td><td style="vertical-align:top"><p>Decreases theophylline clearance.</p></td><td style="vertical-align:top"><p>60% increase</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Troleandomycin</p></td><td style="vertical-align:top"><p>Similar to erythromycin.</p></td><td style="vertical-align:top"><p>33 - 100% increase depending on troleandomycin dose.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Verapamil</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Similar to disulfiram.</p></td><td style="vertical-align:top"><p>20% increase</p></td></tr></tbody></table><p><strong>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Refer to<strong> <em>PRECAUTIONS</em>, Drug Interactions </strong>for further information regarding table.</p><p><strong>**</strong>&nbsp;&nbsp; Average effect on steady-state theophylline concentration or other clinical effect for pharmacologic interactions. Individual patients may experience larger changes in serum theophylline concentration than the value listed.</p><p>&nbsp;</p><p><strong>Table 4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drugs That Have Been Documented Not to Interact With Theophylline or</strong></p><p><strong>Drugs That Produce No Clinically Significant Interaction With Theophylline*</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:684px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>albuterol,</p><p>&nbsp;&nbsp; systemic and inhaled</p><p>amoxicillin</p><p>ampicillin,</p><p>&nbsp;&nbsp; with or without sulbactam</p><p>atenolol</p><p>azithromycin</p><p>caffeine,</p><p>&nbsp;&nbsp; dietary ingestion</p><p>cefaclor</p><p>co-trimoxazole</p><p>&nbsp;&nbsp; (trimethoprim and sulfamethoxazole)</p><p>diltiazem</p><p>dirithromycin</p><p>enflurane</p><p>famotidine</p><p>felodipine</p><p>finasteride</p><p>hydrocortisone</p><p>isoflurane</p><p>isoniazid</p><p>isradipine</p><p>influenza vaccine</p><p>ketoconazole</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>lomefloxacin</p><p>mebendazole</p><p>medroxyprogesterone</p><p>methylprednisolone</p><p>metronidazole</p><p>metoprolol</p><p>nadolol</p><p>nifedipine</p><p>nizatidine</p><p>norfloxacin</p><p>ofloxacin</p><p>omeprazole</p><p>prednisone, prednisolone</p><p>ranitidine</p><p>rifabutin</p><p>roxithromycin</p><p>sorbitol</p><p>&nbsp; (purgative doses do not inhibit</p><p>&nbsp; theophylline absorption)</p><p>sucralfate</p><p>terbutaline, systemic</p><p>terfenadine</p><p>tetracycline</p><p>tocainide</p></td></tr></tbody></table><p><strong>* </strong>Refer to<strong> <em>PRECAUTIONS</em>, Drug Interactions </strong>for information regarding table.</p><p><strong>&nbsp;</strong></p><p><strong>The Effect of Other Drugs on Theophylline Serum Concentration Measurements:</strong></p><p>Most serum theophylline assays in clinical use are immunoassays which are specific for theophylline. Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays. Some drugs (e.g., cefazolin, cephalothin), however, may interfere with certain HPLC techniques. Caffeine and xanthine metabolites in neonates or patients with renal dysfunction may cause the reading from some dry reagent office methods to be higher than the actual serum theophylline concentration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy: </strong></p><p>There are no adequate and well controlled studies in pregnant women. Additionally, there are no teratogenicity studies in nonrodents (e.g., rabbits). Theophylline was not shown to be teratogenic in CD-1 mice at oral doses up to 400 mg/kg, approximately 2.0 times the human dose on a mg/m<sup>2</sup> basis or in CD-1 rats at oral doses up to 260 mg/kg, approximately 3.0 times the recommended human dose on a mg/m<sup>2</sup> basis.&nbsp; At a dose of 220 mg/kg, embryotoxicity was observed in rats in the absence of maternal toxicity.</p><p><strong>&nbsp;</strong></p><p><strong>Nursing Mothers:</strong></p><p>Theophylline is excreted into breast milk and may cause irritability or other signs of mild toxicity in nursing human infants. The concentration of theophylline in breast milk is about equivalent to the maternal serum concentration. An infant ingesting a liter of breast milk containing 10&nbsp;‑&nbsp;20&nbsp;mcg/mL of theophylline per day is likely to receive 10 - 20 mg of theophylline per day. Serious adverse effects in the infant are unlikely unless the mother has toxic serum theophylline concentrations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not Applicable</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions associated with theophylline are generally mild when peak serum theophylline concentrations are &lt;20 mcg/mL and mainly consist of transient caffeine-like adverse effects such as nausea, vomiting, headache, and insomnia. When peak serum theophylline concentrations exceed<br />20 mcg/mL, however, theophylline produces a wide range of adverse reactions including persistent vomiting, cardiac arrhythmias, and intractable seizures which can be lethal (see <strong><em>OVERDOSAGE</em></strong>).</p><p>&nbsp;</p><p>Other adverse reactions that have been reported at serum theophylline concentrations &lt;20&nbsp;mcg/mL include diarrhea, irritability, restlessness, fine skeletal muscle tremors, and transient diuresis. In patients with hypoxia secondary to COPD, multifocal atrial tachycardia and flutter have been reported at serum theophylline concentrations &ge;15 mcg/mL. There have been a few isolated reports of seizures at serum theophylline concentrations &lt;20 mcg/mL in patients with an underlying neurological disease or in elderly patients.</p><p>&nbsp;</p><p>The occurrence of seizures in elderly patients with serum theophylline concentrations<br />&lt;20 mcg/mL may be secondary to decreased protein binding resulting in a larger proportion of the total serum theophylline concentration in the pharmacologically active unbound form. The clinical characteristics of the seizures reported in patients with serum theophylline concentrations &lt;20 mcg/mL have generally been milder than seizures associated with excessive serum theophylline concentrations resulting from an overdose (i.e., they have generally been transient, often stopped without anticonvulsant therapy, and did not result in neurological residua).</p><p>&nbsp;</p><p>Products containing aminophylline may rarely produce severe allergic reactions of the skin, including exfoliative dermatitis, after systemic administration in a patient who has been previously sensitized by topical application of a substance containing ethylenediamine. In such patients skin patch tests are positive for ethylenediamine, a component of aminophylline, and negative for theophylline. Pharmacists and other individuals who experience repeated skin exposure while physically handling aminophylline may develop a contact dermatitis due to the ethylenediamine component.</p><p>&nbsp;</p><p><strong>Table 5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Manifestations of Theophylline Toxicity*</strong></p><p><strong>Percentage of Patients Reported With Sign or Symptom</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:684px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Acute Overdose</strong></p><p><strong>(Large Single Ingestion)</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Chronic Overdosage</strong></p><p><strong>(Multiple Excessive Doses)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Sign/Symptom</strong></p></td><td style="vertical-align:top"><p><strong>Study 1</strong></p><p><strong>(n=157)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Study 2</strong></p><p><strong>(n=14)</strong></p></td><td style="vertical-align:top"><p><strong>Study 1</strong></p><p><strong>(n=92)</strong></p></td><td style="vertical-align:top"><p><strong>Study 2</strong></p><p><strong>(n=102)</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Asymptomatic</u></p></td><td style="vertical-align:top"><p>NR**</p></td><td colspan="2" style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>NR**</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p><u>Gastrointestinal</u></p><p>&nbsp;&nbsp; Vomiting</p><p>&nbsp;&nbsp; Abdominal pain</p><p>&nbsp;&nbsp; Diarrhea</p><p>&nbsp;&nbsp; Hematemesis</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>73</p><p>NR**</p><p>NR**</p><p>NR**</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>93</p><p>21</p><p>0</p><p>0</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>30</p><p>NR**</p><p>NR**</p><p>NR**</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>61</p><p>12</p><p>14</p><p>2</p></td></tr><tr><td style="vertical-align:top"><p><u>Metabolic/Other</u></p><p>&nbsp;&nbsp; Hypokalemia</p><p>&nbsp;&nbsp; Hyperglycemia</p><p>&nbsp;&nbsp; Acid/base disturbance</p><p>&nbsp;&nbsp; Rhabdomyolysis</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>85</p><p>98</p><p>34</p><p>NR**</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>79</p><p>NR**</p><p>21</p><p>7</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>44</p><p>18</p><p>9</p><p>NR**</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>43</p><p>NR**</p><p>5</p><p>0</p></td></tr><tr><td style="vertical-align:top"><p><u>Cardiovascular</u></p><p>&nbsp;&nbsp; Sinus tachycardia</p><p>&nbsp;&nbsp; Other supraventricular</p><p>&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tachycardias</p><p>&nbsp;&nbsp; Ventricular premature beats</p><p>&nbsp;&nbsp; Atrial fibrillation or flutter</p><p>&nbsp;&nbsp; Multifocal atrial tachycardia</p><p>&nbsp;&nbsp; Ventricular arrhythmias with</p><p>&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hemodynamic instability</p><p>&nbsp;&nbsp; Hypotension/shock</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>100</p><p>2</p><p>&nbsp;</p><p>3</p><p>1</p><p>0</p><p>7</p><p>&nbsp;</p><p>NR**</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>86</p><p>21</p><p>&nbsp;</p><p>21</p><p>NR**</p><p>NR**</p><p>14</p><p>&nbsp;</p><p>21</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>100</p><p>12</p><p>&nbsp;</p><p>10</p><p>12</p><p>2</p><p>40</p><p>&nbsp;</p><p>NR**</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>62</p><p>14</p><p>&nbsp;</p><p>19</p><p>NR**</p><p>NR**</p><p>0</p><p>&nbsp;</p><p>8</p></td></tr><tr><td style="vertical-align:top"><p><u>Neurologic</u></p><p>&nbsp;&nbsp; Nervousness</p><p>&nbsp;&nbsp; Tremors</p><p>&nbsp;&nbsp; Disorientation</p><p>&nbsp;&nbsp; Seizures</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>NR**</p><p>38</p><p>NR**</p><p>5</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>64</p><p>29</p><p>7</p><p>14</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>NR**</p><p>16</p><p>NR**</p><p>14</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>21</p><p>14</p><p>11</p><p>5</p></td></tr><tr><td style="vertical-align:top"><p><u>Death</u></p></td><td style="vertical-align:top"><p>3</p></td><td colspan="2" style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; These data are derived from two studies in patients with serum theophylline concentrations<br />&gt;30 mcg/mL. In the first study (Study #1 &ndash; Shanon, Ann Intern Med 1993;119:1161-67), data were prospectively collected from 249 consecutive cases of theophylline toxicity referred to a regional poison center for consultation. In the second study (Study #2 &ndash; Sessler, Am J Med 1990; 88:567-76), data were retrospectively collected from 116 cases with serum theophylline concentrations &gt;30 mcg/mL among 6000 blood samples obtained for measurement of serum theophylline concentrations in three emergency departments. Differences in the incidence of manifestations of theophylline toxicity between the two studies may reflect sample selection as a result of study design (e.g., in Study #1, 48% of the patients had acute intoxications versus only 10% in Study #2) and different methods of reporting results.</p><p>**&nbsp;&nbsp;&nbsp; NR = Not reported in a comparable manner</p><p><strong>&nbsp;</strong></p><p><strong>Reporting</strong><strong> of suspected adverse reactions:</strong></p><p>Reporting suspected adverse reactions after <u>marketing</u> authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions <u>according to their local country requirements</u>.</p><p><strong>&nbsp;</strong></p><p><strong>To </strong><strong>report</strong><strong> </strong><strong>side effects: </strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp; Call center: 19999</p><p>&middot;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>General:</strong></p><p>The chronicity and pattern of theophylline overdosage significantly influences clinical manifestations of toxicity, management and outcome. There are two common presentations: 1)&nbsp;<em>acute overdose</em>, i.e., infusion of an excessive loading dose or excessive maintenance infusion rate for less than 24 hours, and 2) <em>chronic overdosage</em>, i.e., excessive maintenance infusion rate for greater than 24 hours. The most common causes of chronic theophylline overdosage include clinician prescribing of an excessive dose or a normal dose in the presence of factors known to decrease the rate of theophylline clearance and increasing the dose in response to an exacerbation of symptoms without first measuring the serum theophylline concentration to determine whether a dose increase is safe.</p><p>&nbsp;</p><p>Several studies have described the clinical manifestations of theophylline overdose following oral administration and attempted to determine the factors that predict life-threatening toxicity. In general, patients who experience an acute overdose are less likely to experience seizures than patients who have experienced a chronic overdosage, unless the peak serum theophylline concentration is &gt;100 mcg/mL. After a chronic overdosage, generalized seizures, life-threatening cardiac arrhythmias, and death may occur at serum theophylline concentrations &gt;30 mcg/mL. The severity of toxicity after chronic overdosage is more strongly correlated with the patient&rsquo;s age than the peak serum theophylline concentration; patients &gt;60 years are at the greatest risk for severe toxicity and mortality after a chronic overdosage. Pre-existing or concurrent disease may also significantly increase the susceptibility of a patient to a particular toxic manifestation, e.g., patients with neurologic disorders have an increased risk of seizures and patients with cardiac disease have an increased risk of cardiac arrhythmias for a given serum theophylline concentration compared to patients without the underlying disease.</p><p>&nbsp;</p><p>The frequency of various reported manifestations of oral theophylline overdose according to the mode of overdose are listed in <strong>Table 5</strong>.</p><p>&nbsp;</p><p>Other manifestations of theophylline toxicity include increases in serum calcium, creatine kinase, myoglobin and leukocyte count, decreases in serum phosphate and magnesium, acute myocardial infarction, and urinary retention in men with obstructive uropathy.</p><p>&nbsp;</p><p>Seizures associated with serum theophylline concentrations &gt;30 mcg/mL are often resistant to anticonvulsant therapy and may result in irreversible brain injury if not rapidly controlled. Death from theophylline toxicity is most often secondary to cardiorespiratory arrest and/or hypoxic encephalopathy following prolonged generalized seizures or intractable cardiac arrhythmias causing hemodynamic compromise.</p><p><strong>&nbsp;</strong></p><p><strong>Overdose Management:</strong></p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>General Recommendations for Patients with Symptoms of Theophylline Overdose or Serum Theophylline Concentrations &gt;30 mcg/mL While Receiving Intravenous Theophylline.</u></strong></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stop the theophylline infusion.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; While simultaneously instituting treatment, contact a regional poison center to obtain updated information and advice on individualizing the recommendations that follow.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Institute supportive care, including establishment of intravenous access, maintenance of the airway, and electrocardiographic monitoring.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Treatment of seizures</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Because of the high morbidity and mortality associated with theophylline-induced seizures, treatment should be rapid and aggressive. Anticonvulsant therapy should be initiated with an intravenous benzodiazepine, e.g., diazepam, in increments of 0.1 - 0.2 mg/kg every 1 - 3 minutes until seizures are terminated. Repetitive seizures should be treated with a loading dose of phenobarbital (20 mg/kg infused over 30 - 60 minutes). Case reports of theophylline overdose in humans and animal studies suggest that phenytoin is ineffective in terminating theophylline-induced seizures. The doses of benzodiazepines and phenobarbital required to terminate theophylline-induced seizures are close to the doses that may cause severe respiratory depression or respiratory arrest; the clinician should therefore be prepared to provide assisted ventilation. Elderly patients and patients with COPD may be more susceptible to the respiratory depressant effects of anticonvulsants. Barbiturate-induced coma or administration of general anesthesia may be required to terminate repetitive seizures or status epilepticus. General anesthesia should be used with caution in patients with theophylline overdose because fluorinated volatile anesthetics may sensitize the myocardium to endogenous catecholamines released by theophylline. Enflurane appears less likely to be associated with this effect than halothane and may, therefore, be safer. Neuromuscular blocking agents alone should not be used to terminate seizures since they abolish the musculoskeletal manifestations without terminating seizure activity in the brain.</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Anticipate Need for Anticonvulsants</u>&nbsp; In patients with theophylline overdose who are at high risk for theophylline-induced seizures, e.g., patients with acute overdoses and serum theophylline concentrations &gt;100 mcg/mL or chronic overdosage in patients &gt;60 years of age with serum theophylline concentrations &gt;30 mcg/mL, the need for anticonvulsant therapy should be anticipated. A benzodiazepine such as diazepam should be drawn into a syringe and kept at the patient&rsquo;s bedside and medical personnel qualified to treat seizures should be immediately available. In selected patients at high risk for theophylline-induced seizures, consideration should be given to the administration of prophylactic anticonvulsant therapy. Situations where prophylactic anticonvulsant therapy should be considered in high risk patients include anticipated delays in instituting methods for extracorporeal removal of theophylline (e.g., transfer of a high risk patient from one health care facility to another for extracorporeal removal) and clinical circumstances that significantly interfere with efforts to enhance theophylline clearance (e.g., a neonate where dialysis may not be technically feasible or a patient with vomiting unresponsive to antiemetics who is unable to tolerate multiple-dose oral activated charcoal). In animal studies, prophylactic administration of phenobarbital, <u>but not phenytoin</u>, has been shown to delay the onset of theophylline-induced generalized seizures and to increase the dose of theophylline required to induce seizures (i.e., markedly increases the LD<sub>50</sub>). Although there are no controlled studies in humans, a loading dose of intravenous phenobarbital (20&nbsp;mg/kg infused over 60 minutes) may delay or prevent life-threatening seizures in high risk patients while efforts to enhance theophylline clearance are continued. Phenobarbital may cause respiratory depression, particularly in elderly patients and patients with COPD.</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Treatment of cardiac arrhythmias</u> Sinus tachycardia and simple ventricular premature beats are not harbingers of life-threatening arrhythmias, they do not require treatment in the absence of hemodynamic compromise, and they resolve with declining serum theophylline concentrations. Other arrhythmias, especially those associated with hemodynamic compromise, should be treated with antiarrhythmic therapy appropriate for the type of arrhythmia.</p><p>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Serum Theophylline Concentration Monitoring</u> The serum theophylline concentration should be measured immediately upon presentation, 2 - 4 hours later, and then at sufficient intervals, e.g., every 4 hours, to guide treatment decisions and to assess the effectiveness of therapy. Serum theophylline concentrations may continue to increase after presentation of the patient for medical care as a result of continued absorption of theophylline from the gastrointestinal tract. Serial monitoring of serum theophylline serum concentrations should be continued until it is clear that the concentration is no longer rising and has returned to nontoxic levels.</p><p>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>General Monitoring Procedures</u> Electrocardiographic monitoring should be initiated on presentation and continued until the serum theophylline level has returned to a nontoxic level. Serum electrolytes and glucose should be measured on presentation and at appropriate intervals indicated by clinical circumstances. Fluid and electrolyte abnormalities should be promptly corrected. <strong>Monitoring and treatment should be continued until the serum concentration decreases below 20 mcg/mL.</strong></p><p>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Enhance clearance of theophylline</u> Multiple-dose oral activated charcoal (e.g., 0.5 mg/kg up to 20 g, every two hours) increases the clearance of theophylline at least twofold by adsorption of theophylline secreted into gastrointestinal fluids. Charcoal must be retained in, and pass through, the gastrointestinal tract to be effective; emesis should therefore be controlled by administration of appropriate antiemetics. Alternatively, the charcoal can be administered continuously through a nasogastric tube in conjunction with appropriate antiemetics. A single dose of sorbitol may be administered with the activated charcoal to promote stooling to facilitate clearance of the adsorbed theophylline from the gastrointestinal tract. Sorbitol alone does not enhance clearance of theophylline and should be dosed with caution to prevent excessive stooling which can result in severe fluid and electrolyte imbalances. Commercially available fixed combinations of liquid charcoal and sorbitol should be avoided in young children and after the first dose in adolescents and adults since they do not allow for individualization of charcoal and sorbitol dosing. In patients with intractable vomiting, extracorporeal methods of theophylline removal should be instituted (see <strong><em>OVERDOSAGE</em></strong>, <strong>Extracorporeal Removal</strong>).</p><p><strong>&nbsp;</strong></p><p><strong>Specific Recommendations:</strong></p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Acute Overdose (e.g., excessive loading dose or excessive infusion rate &lt;24 hours)</u></strong></p><p>A.&nbsp;&nbsp;&nbsp; <u>Serum Concentration &gt;20 &lt;30 mcg/mL</u></p><p>1.&nbsp;&nbsp; Stop the theophylline infusion.</p><p>2.&nbsp;&nbsp; Monitor the patient and obtain a serum theophylline concentration in 2 - 4 hours to insure that the concentration is decreasing.</p><p>B.&nbsp;&nbsp;&nbsp;&nbsp; <u>Serum Concentration &gt;30 &lt;100 mcg/mL</u></p><p>1.&nbsp;&nbsp; Stop the theophylline infusion.</p><p>2.&nbsp;&nbsp; Administer multiple dose oral activated charcoal and measures to control emesis.</p><p>3.&nbsp;&nbsp; Monitor the patient and obtain serial theophylline concentrations every 2 - 4 hours to gauge the effectiveness of therapy and to guide further treatment decisions.</p><p>4.&nbsp;&nbsp; Institute extracorporeal removal if emesis, seizures, or cardiac arrhythmias cannot be adequately controlled (see <strong><em>OVERDOSAGE</em></strong>, <strong>Extracorporeal Removal</strong>).</p><p>C.&nbsp;&nbsp;&nbsp;&nbsp; <u>Serum Concentration &gt;100 mcg/mL</u></p><p>1.&nbsp;&nbsp; Stop the theophylline infusion.</p><p>2.&nbsp;&nbsp; Consider prophylactic anticonvulsant therapy.</p><p>3.&nbsp;&nbsp; Administer multiple-dose oral activated charcoal and measures to control emesis.</p><p>4.&nbsp;&nbsp; Consider extracorporeal removal, even if the patient has not experienced a seizure (see <strong><em>OVERDOSAGE</em></strong>, <strong>Extracorporeal Removal</strong>).</p><p>5.&nbsp;&nbsp; Monitor the patient and obtain serial theophylline concentrations every 2 - 4 hours to gauge the effectiveness of therapy and to guide further treatment decisions.</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Chronic Overdosage (e.g., excessive infusion rate for greater than 24 hours)</u></strong></p><p>A.&nbsp;&nbsp;&nbsp; <u>Serum Concentration &gt;20 &lt;30 mcg/mL (with manifestations of theophylline toxicity)</u></p><p>1.&nbsp;&nbsp; Stop the theophylline infusion.</p><p>2.&nbsp;&nbsp; Monitor the patient and obtain a serum theophylline concentration in 2 - 4 hours to insure that the concentration is decreasing.</p><p>B.&nbsp;&nbsp;&nbsp;&nbsp; <u>Serum Concentration &gt;30 mcg/mL in patients &lt;60 years of age</u></p><p>1.&nbsp;&nbsp; Stop the theophylline infusion.</p><p>2.&nbsp;&nbsp; Administer multiple-dose oral activated charcoal and measures to control emesis.</p><p>3.&nbsp;&nbsp; Monitor the patient and obtain serial theophylline concentrations every 2 - 4 hours to gauge the effectiveness of therapy and to guide further treatment decisions.</p><p>4.&nbsp;&nbsp; Institute extracorporeal removal if emesis, seizures, or cardiac arrhythmias cannot be adequately controlled (see <strong><em>OVERDOSAGE</em></strong>, <strong>Extracorporeal Removal</strong>).</p><p>C.&nbsp;&nbsp;&nbsp;&nbsp; <u>Serum Concentration &gt;30 mcg/mL in patients &ge;60 years of age</u></p><p>1.&nbsp;&nbsp; Stop the theophylline infusion.</p><p>2.&nbsp;&nbsp; Consider prophylactic anticonvulsant therapy.</p><p>3.&nbsp;&nbsp; Administer multiple-dose oral activated charcoal and measures to control emesis.</p><p>4.&nbsp;&nbsp; Consider extracorporeal removal even if the patient has not experienced a seizure (see <strong><em>OVERDOSAGE</em></strong>, <strong>Extracorporeal Removal</strong>).</p><p>5.&nbsp;&nbsp; Monitor the patient and obtain serial theophylline concentrations every 2 - 4 hours to gauge the effectiveness of therapy and to guide further treatment decisions.</p><p><strong>&nbsp;</strong></p><p><strong>Extracorporeal Removal:</strong></p><p>Increasing the rate of theophylline clearance by extracorporeal methods may rapidly decrease serum concentrations, but the risks of the procedure must be weighed against the potential benefit. Charcoal hemoperfusion is the most effective method of extracorporeal removal, increasing theophylline clearance up to six fold, but serious complications, including hypotension, hypocalcemia, platelet consumption and bleeding diatheses may occur. Hemodialysis is about as efficient as multiple-dose oral activated charcoal and has a lower risk of serious complications than charcoal hemoperfusion. Hemodialysis should be considered as an alternative when charcoal hemoperfusion is not feasible and multiple-dose oral charcoal is ineffective because of intractable emesis. Serum theophylline concentrations may rebound<br />5 - 10 mcg/mL after discontinuation of charcoal hemoperfusion or hemodialysis due to redistribution of theophylline from the tissue compartment. Peritoneal dialysis is ineffective for theophylline removal; exchange transfusions in neonates have been minimally effective.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Mechanism of Action:</strong></p><p>Theophylline has two distinct actions in the airways of patients with reversible obstruction; smooth muscle relaxation (i.e., bronchodilation) and suppression of the response of the airways to stimuli (i.e., nonbronchodilator prophylactic effects). While the mechanisms of action of theophylline are not known with certainty, studies in animals suggest that bronchodilation is mediated by the inhibition of two isozymes of phosphodiesterase (PDE III and, to a lesser extent, PDE IV), while nonbronchodilator prophylactic actions are probably mediated through one or more different molecular mechanisms, that do not involve inhibition of PDE III or antagonism of adenosine receptors. Some of the adverse effects associated with theophylline appear to be mediated by inhibition of PDE III (e.g., hypotension, tachycardia, headache, and emesis) and adenosine receptor antagonism (e.g., alterations in cerebral blood flow).</p><p>&nbsp;</p><p>Theophylline increases the force of contraction of diaphragmatic muscles. This action appears to be due to enhancement of calcium uptake through an adenosine-mediated channel.</p><p>&nbsp;</p><p><strong>Serum Concentration-Effect Relationship:</strong></p><p>Bronchodilation occurs over the serum theophylline concentration range of 5 - 20 mcg/mL. Clinically important improvement in symptom control and pulmonary function has been found in most studies to require serum theophylline concentrations &gt;10 mcg/mL. At serum theophylline concentrations<br />&gt;20 mcg/mL, both the frequency and severity of adverse reactions increase. In general, maintaining the average serum theophylline concentration between 10 and 15 mcg/mL will achieve most of the drug&rsquo;s potential therapeutic benefit while minimizing the risk of serious adverse events.</p><p>&nbsp;</p><p><strong>Clinical Studies:</strong></p><p>Inhaled beta-2 selective agonists and systemically administered corticosteroids are the treatments of first choice for management of acute exacerbations of asthma. The results of controlled clinical trials on the efficacy of adding intravenous theophylline to inhaled beta-2 selective agonists and systemically administered corticosteroids in the management of acute exacerbations of asthma have been conflicting. Most studies in patients treated for acute asthma exacerbations in an emergency department have shown that addition of intravenous theophylline does not produce greater bronchodilation and increases the risk of adverse effects. In contrast, other studies have shown that addition of intravenous theophylline is beneficial in the treatment of acute asthma exacerbations in patients requiring hospitalization, particularly in patients who are not responding adequately to inhaled beta-2 selective agonists.</p><p>In patients with chronic obstructive pulmonary disease (COPD), clinical studies have shown that theophylline decreases dyspnea, air trapping, the work of breathing, and improves contractility of diaphragmatic muscles with little or no improvement in pulmonary function measurements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Overview</u></strong></p><p>The pharmacokinetics of theophylline vary widely among similar patients and cannot be predicted by age, sex, body weight or other demographic characteristics. In addition, certain concurrent illnesses and alterations in normal physiology (see <strong>Table 6</strong>) and co-administration of other drugs (see <strong>Table 3</strong>) can significantly alter the pharmacokinetic characteristics of theophylline. Within-subject variability in metabolism has also been reported in some studies, especially in acutely ill patients.</p><p>&nbsp;</p><p>It is, therefore, recommended that serum theophylline concentrations be measured frequently in acutely ill patients receiving intravenous theophylline (e.g., at 24-hr. intervals). More frequent measurements should be made during the initiation of therapy and in the presence of any condition that may significantly alter theophylline clearance (see <strong><em>PRECAUTIONS</em></strong>,<strong> Effects on Laboratory Tests</strong>).</p><p>&nbsp;</p><p><strong>Table 6.&nbsp; Mean and Range of Total Body Clearance and Half-Life of Theophylline Related to Age</strong></p><p><strong>and Altered Physiological States&para;</strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:676px"><tbody><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Population Characteristics</strong></p><p><strong>Age</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Total Body Clearance*</strong></p><p><strong>Mean (Range)<sup>&dagger;&dagger;</sup></strong></p><p><strong>(mL/kg/min)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Half-Life</strong></p><p><strong>Mean (Range)<sup>&dagger;&dagger;</sup></strong></p><p><strong>(hr)</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>Premature neonates</p><p>postnatal age 3 - 15 days</p><p>postnatal age 25 - 57 days</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>0.29 (0.09 - 0.49)</p><p>0.64 (0.04 - 1.2)</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>30 (17 - 43)</p><p>20 (9.4 - 30.6)</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Term infants</p><p>postnatal age 1 - 2 days</p><p>postnatal age 3 - 30 weeks</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>NR<sup>&dagger;</sup>&nbsp;</p><p>NR<sup>&dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>25.7 (25 - 26.5)</p><p>11 (6 - 29)</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Children</p><p>1 - 4 years</p><p>4 - 12 years</p><p>13 - 15 years</p><p>6 - 17 years</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>1.7 (0.5 - 2.9)</p><p>1.6 (0.8 - 2.4)</p><p>0.9 (0.48 - 1.3)</p><p>1.4 (0.2 - 2.6)</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>3.4 (1.2 - 5.6)</p><p>NR<sup>&dagger;</sup></p><p>NR<sup>&dagger;</sup></p><p>3.7 (1.5 - 5.9)</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Adults (16 - 60 years)</p><p>otherwise healthy</p><p>nonsmoking asthmatics</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>0.65 (0.27 - 1.03)</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>8.7 (6.1 - 12.8)</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Elderly (&gt;60 years)</p><p>nonsmokers with normal cardiac,</p><p>liver, and renal function</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>0.41 (0.21 - 0.61)</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>9.8 (1.6 - 18)</p></td></tr><tr><td colspan="4" style="vertical-align:bottom"><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Concurrent Illness Or Altered Physiological State</u></strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Acute pulmonary edema</p></td><td colspan="2" style="vertical-align:top"><p>0.33** (0.07 - 2.45)</p></td><td colspan="2" style="vertical-align:top"><p>19** (3.1 - 8.2)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>COPD- &gt;60 years, stable</p><p>nonsmoker &gt;1 year</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>0.54 (0.44 - 0.64)</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>11 (9.4 - 12.6)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>COPD with cor pulmonale</p></td><td colspan="2" style="vertical-align:top"><p>0.48 (0.08 - 0.88)</p></td><td colspan="2" style="vertical-align:top"><p>NR<sup>&dagger;</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Cystic fibrosis (14 - 28 years)</p></td><td colspan="2" style="vertical-align:top"><p>1.25 (0.31 - 2.2)</p></td><td colspan="2" style="vertical-align:top"><p>6 (1.8 - 10.2)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Fever associated with acute viral respiratory</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>illness (children 9 - 15 years)</p></td><td colspan="2" style="vertical-align:top"><p>NR<sup>&dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>7 (1.0 - 13)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Liver disease &ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cirrhosis</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acute hepatitis</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cholestasis</p></td><td colspan="2" style="vertical-align:top"><p>0.31** (0.1 - 0.7)</p><p>0.35 (0.25 - 0.45)</p><p>0.65 (0.25 - 1.45)</p></td><td colspan="2" style="vertical-align:top"><p>32**&nbsp; (10 - 56)</p><p>19.2 (16.6 - 21.8)</p><p>14.4 (5.7 - 31.8)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Pregnancy &ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1st trimester</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2nd trimester</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3rd trimester</p></td><td colspan="2" style="vertical-align:top"><p>NR<sup>&dagger;</sup></p><p>NR<sup>&dagger;</sup></p><p>NR<sup>&dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>8.5 (3.1 - 13.9)</p><p>8.8 (3.8 - 13.8)</p><p>13 (8.4 - 17.6)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Sepsis with multi-organ failure</p></td><td colspan="2" style="vertical-align:top"><p>0.47 (0.19 - 1.9)</p></td><td colspan="2" style="vertical-align:top"><p>18.8 (6.3 - 24.1)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Thyroid disease &ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypothyroid</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hyperthyroid</p><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>0.38 (0.13 - 0.57)</p><p>0.8 (0.68 - 0.97)</p></td><td colspan="2" style="vertical-align:top"><p>11.6 (8.2 - 25)</p><p>4.5 (3.7 - 5.6)</p></td><td><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><strong>&para;</strong>&nbsp;&nbsp; For various North American patient populations from literature reports. Different rates of elimination and consequent dosage requirements have been observed among other peoples.</p><p>*&nbsp;&nbsp;&nbsp; Clearance represents the volume of blood completely cleared of theophylline by the liver in one minute. Values listed were generally determined at serum theophylline concentrations,<br />&lt;20 mcg/mL; clearance may decrease and half-life may increase at higher serum concentrations due to nonlinear pharmacokinetics.</p><p><sup>&dagger;&dagger;</sup>&nbsp;&nbsp; Reported range or estimated range (mean &plusmn; 2 SD) where actual range not reported.</p><p><sup>&dagger;</sup>&nbsp;&nbsp;&nbsp; NR = not reported or not reported in a comparable format.</p><p>**&nbsp; Median</p><p><strong>&nbsp;</strong></p><p><strong>Note:</strong> In addition to the factors listed above, theophylline clearance is increased and half-life decreased by low carbohydrate/high protein diets, parenteral nutrition, and daily consumption of charcoal-broiled beef. A high carbohydrate/low protein diet can decrease the clearance and prolong the half-life of theophylline.</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Distribution</u></strong></p><p>Once theophylline enters the systemic circulation, about 40% is bound to plasma protein, primarily albumin. Unbound theophylline distributes throughout body water, but distributes poorly into body fat. The apparent volume of distribution of theophylline is approximately 0.45 L/kg(range0.3- 0.7 L/kg) based on ideal body weight. Theophylline passes freely across the placenta, into breast milk and into the cerebrospinal fluid (CSF). Saliva theophylline concentrations approximate unbound serum concentrations, but are not reliable for routine or therapeutic monitoring unless special techniques are used. An increase in the volume of distribution of theophylline, primarily due to reduction in plasma protein binding, occurs in premature neonates, patients with hepatic cirrhosis, uncorrected acidemia, the elderly and in women during the third trimester of pregnancy. In such cases, the patient may show signs of toxicity at total (bound + unbound) serum concentrations of theophylline in the therapeutic range (10 - 20 mcg/mL) due to elevated concentrations of the pharmacologically active unbound drug. Similarly, a patient with decreased theophylline binding may have a sub-therapeutic total drug concentration while the pharmacologically active unbound concentration is in the therapeutic range. If only total serum theophylline concentration is measured, this may lead to an unnecessary and potentially dangerous dose increase. In patients with reduced protein binding, measurement of unbound serum theophylline concentration provides a more reliable means of dosage adjustment than measurement of total serum theophylline concentration. Generally, concentrations of unbound theophylline should be maintained in the range of 6 - 12 mcg/mL.</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Metabolism</u></strong></p><p>In adults and children beyond one year of age, approximately 90% of the dose is metabolized in the liver. Biotransformation takes place through demethylation to 1-methylxanthine and 3-methylxanthine and hydroxylation to 1,3-dimethyluric acid. 1-methylxanthine is further hydroxylated, by xanthine oxidase, to 1-methyluric acid. About 6% of a theophylline dose is N‑methylated to caffeine. Theophylline demethylation to 3-methylxanthine is catalyzed by cytochrome P-450 1A2, while cytochromes P-450 2E1 and P-450 3A3 catalyze the hydroxylation to 1,3-dimethyluric acid. Demethylation to 1-methylxanthine appears to be catalyzed either by cytochrome P-450 1A2 or a closely related cytochrome. In neonates, the N-demethylation pathway is absent while the function of the hydroxylation pathway is markedly deficient. The activity of these pathways slowly increases to maximal levels by one year of age.</p><p>&nbsp;</p><p>Caffeine and 3-methylxanthine are the only theophylline metabolites with pharmacologic activity. 3-methylxanthine has approximately one tenth the pharmacologic activity of theophylline and serum concentrations in adults with normal renal function are &lt;1 mcg/mL. In patients with end-stage renal disease, 3-methylxanthine may accumulate to concentrations that approximate the unmetabolized theophylline concentration. Caffeine concentrations are usually undetectable in adults regardless of renal function. In neonates, caffeine may accumulate to concentrations that approximate the unmetabolized theophylline concentration and thus, exert a pharmacologic effect.</p><p>&nbsp;</p><p>Both the N-demethylation and hydroxylation pathways of theophylline biotransformation are capacity-limited. Due to the wide intersubject variability of the rate of theophylline metabolism, nonlinearity of elimination may begin in some patients at serum theophylline concentrations<br />&lt;10 mcg/mL. Since this nonlinearity results in more than proportional changes in serum theophylline concentrations with changes in dose, it is advisable to make increases or decreases in dose in small increments in order to achieve desired changes in serum theophylline concentrations (See <strong><em>DOSAGE AND ADMINISTRATION</em></strong>, <strong>Table 2</strong>). Accurate prediction of dose-dependency of theophylline metabolism in patients <em>a priori</em> is not possible, but patients with very high initial clearance rates (i.e., low steady state serum theophylline concentrations at above average doses) have the greatest likelihood of experiencing large changes in serum theophylline concentration in response to dosage changes.</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Excretion</u></strong></p><p>In neonates, approximately 50% of the theophylline dose is excreted unchanged in the urine. Beyond the first three months of life, approximately 10% of the theophylline dose is excreted unchanged in the urine. The remainder is excreted in the urine mainly as 1,3-dimethyluric acid (35&nbsp;‑&nbsp;40%), 1-methyluric acid (20 - 25%) and 3-methylxanthine (15 - 20%). Since little theophylline is excreted unchanged in the urine and since active metabolites of theophylline (i.e., caffeine, 3-methylxanthine) do not accumulate to clinically significant levels even in the face of end-stage renal disease, no dosage adjustment for renal insufficiency is necessary in adults and children &gt;3 months of age. In contrast, the large fraction of the theophylline dose excreted in the urine as unchanged theophylline and caffeine in neonates requires careful attention to dose reduction and frequent monitoring of serum theophylline concentrations in neonates with reduced renal function (see <strong><em>WARNINGS</em></strong>).</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Serum Concentrations at Steady State</u></strong></p><p>In a patient who has received no theophylline in the previous 24 hours, a loading dose of intravenous theophylline of 4.6 mg/kg (5.7 mg/kg as aminophylline), calculated on the basis of ideal body weight and administered over 30 minutes, on average, will produce a maximum post-distribution serum concentration of 10 mcg/mL with a range of 6-16 mcg/mL. In non-smoking adults, initiation of a constant intravenous theophylline infusion of 0.4 mg/kg/hr (0.5 mg/kg/hr as aminophylline) at the completion of the loading dose, on average, will result in a steady-state concentration of 10 mcg/mL with a range of 7-26 mcg/mL. The mean and range of steady-state serum concentrations are similar when the average child (age 1&nbsp;to 9 years) is given a loading dose of 4.6 mg/kg theophylline (5.7 mg/kg as aminophylline) followed by a constant intravenous infusion of 0.8 mg/kg/hr (1.0 mg/kg/hr as aminophylline). (See <strong><em>DOSAGE AND ADMINISTRATION</em></strong>.)</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Special Populations (See Table 6 for mean clearance and half-life values)</u></strong></p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><em><u>Geriatric</u></em></strong></p><p>The clearance of theophylline is decreased by an average of 30% in healthy elderly adults<br />(&gt;60 yrs.) compared to healthy young adults. Careful attention to dose reduction and frequent monitoring of serum theophylline concentrations are required in elderly patients (see <strong><em>WARNINGS</em></strong>).</p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><em><u>Pediatrics</u></em></strong></p><p>The clearance of theophylline is very low in neonates (see <strong><em>WARNINGS</em></strong>). Theophylline clearance reaches maximal values by one year of age, remains relatively constant until about 9&nbsp;years of age and then slowly decreases by approximately 50% to adult values at about age 16. Renal excretion of unchanged theophylline in neonates amounts to about 50% of the dose, compared to about 10% in children older than three months and in adults. Careful attention to dosage selection and monitoring of serum theophylline concentrations are required in children (see <strong><em>WARNINGS</em></strong> and <strong><em>DOSAGE AND ADMINISTRATION</em></strong>).</p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><em><u>Gender</u></em></strong></p><p>Gender differences in theophylline clearance are relatively small and unlikely to be of clinical significance. Significant reduction in theophylline clearance, however, has been reported in women on the 20th day of the menstrual cycle and during the third trimester of pregnancy.</p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><em><u>Race</u></em></strong></p><p>Pharmacokinetic differences in theophylline clearance due to race have not been studied.</p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><em><u>Renal Insufficiency</u></em></strong></p><p>Only a small fraction, e.g., about 10%, of the administered theophylline dose is excreted unchanged in the urine of children greater than three months of age and adults. Since little theophylline is excreted unchanged in the urine and since active metabolites of theophylline (i.e., caffeine, 3-methylxanthine) do not accumulate to clinically significant levels even in the face of end-stage renal disease, no dosage adjustment for renal insufficiency is necessary in adults and children &gt;3 months of age. In contrast, approximately 50% of the administered theophylline dose is excreted unchanged in the urine in neonates. Careful attention to dose reduction and frequent monitoring of serum theophylline concentrations are required in neonates with decreased renal function (see <strong><em>WARNINGS</em></strong>).</p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><em><u>Hepatic Insufficiency</u></em></strong></p><p>Theophylline clearance is decreased by 50% or more in patients with hepatic insufficiency (e.g., cirrhosis, acute hepatitis, cholestasis). Careful attention to dose reduction and frequent monitoring of serum theophylline concentrations are required in patients with reduced hepatic function (see <strong><em>WARNINGS</em></strong>).</p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><em><u>Congestive Heart Failure (CHF)</u></em></strong></p><p>Theophylline clearance is decreased by 50% or more in patients with CHF. The extent of reduction in theophylline clearance in patients with CHF appears to be directly correlated to the severity of the cardiac disease. Since theophylline clearance is independent of liver blood flow, the reduction in clearance appears to be due to impaired hepatocyte function rather than reduced perfusion. Careful attention to dose reduction and frequent monitoring of serum theophylline concentrations are required in patients with CHF (see <strong><em>WARNINGS</em></strong>).</p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><em><u>Smokers</u></em></strong></p><p>Tobacco and marijuana smoking appears to increase the clearance of theophylline by induction of metabolic pathways. Theophylline clearance has been shown to increase by approximately 50% in young adult tobacco smokers and by approximately 80% in elderly tobacco smokers compared to nonsmoking subjects. Passive smoke exposure has also been shown to increase theophylline clearance by up to 50%. Abstinence from tobacco smoking for one week causes a reduction of approximately 40% in theophylline clearance. Careful attention to dose reduction and frequent monitoring of serum theophylline concentrations are required in patients who stop smoking (see <strong><em>WARNINGS</em></strong>). Use of nicotine gum has been shown to have no effect on theophylline clearance.</p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><em><u>Fever</u></em></strong></p><p>Fever, regardless of its underlying cause, can decrease the clearance of theophylline. The magnitude and duration of the fever appear to be directly correlated to the degree of decrease of theophylline clearance. Precise data are lacking, but a temperature of 39&deg;C (102&deg;F) for at least 24&nbsp;hours is probably required to produce a clinically significant increase in serum theophylline concentrations. Careful attention to dose reduction and frequent monitoring of serum theophylline concentrations are required in patients with sustained fever (see <strong><em>WARNINGS</em></strong>).</p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><em><u>Miscellaneous</u></em></strong></p><p>Other factors associated with decreased theophylline clearance include the third trimester of pregnancy, sepsis with multiple organ failure, and hypothyroidism. Careful attention to dose reduction and frequent monitoring of serum theophylline concentrations are required in patients with any of these conditions (see <strong><em>WARNINGS</em></strong>). Other factors associated with increased theophylline clearance include hyperthyroidism and cystic fibrosis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Carcinogenesis, Mutagenesis, and Impairment of Fertility:</strong></p><p>&nbsp;</p><p>Long term carcinogenicity studies have been carried out in mice (oral doses 30 - 150 mg/kg) and rats (oral doses 5 - 75 mg/kg). Results are pending.</p><p>&nbsp;</p><p>Theophylline has been studied in Ames salmonella, <em>in vivo</em> and <em>in vitro</em> cytogenetics, micronucleus and Chinese hamster ovary test systems and has not been shown to be genotoxic.</p><p>&nbsp;</p><p>In a 14 week continuous breeding study, theophylline, administered to mating pairs of B6C3F<sub>1</sub> mice at oral doses of 120, 270 and 500 mg/kg (approximately 1.0 - 3.0 times the human dose on a mg/m<sup>2</sup> basis) impaired fertility, as evidenced by decreases in the number of live pups per litter, decreases in the mean number of litters per fertile pair, and increases in the gestation period at the high dose as well as decreases in the proportion of pups born alive at the mid and high dose. In 13&nbsp;week toxicity studies, theophylline was administered to F344 rats and B6C3F<sub>1</sub> mice at oral doses of 40 - 300 mg/kg (approximately 2 times the human dose on a mg/m<sup>2</sup> basis). At the high dose, systemic toxicity was observed in both species including decreases in testicular weight.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ethylenediamine, Nitrogen, Water for Injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Intravenous Admixture Incompatibility:</strong></p><p>Although there have been reports of aminophylline precipitating in acidic media, these reports do not apply to the dilute solutions found in intravenous infusions. Aminophylline injection should not be mixed in a syringe with other drugs but should be added separately to the intravenous solution.</p><p>&nbsp;</p><p>When an intravenous solution containing aminophylline is given &ldquo;piggyback&rdquo;, the intravenous system already in place should be turned off while the aminophylline is infused if there is a potential problem with admixture incompatibility.</p><p>&nbsp;</p><p>Because of the alkalinity of aminophylline containing solutions, drugs known to be alkali labile should be avoided in admixtures. These include epinephrine HCl, norepinephrine bitartrate, isoproterenol HCl and penicillin G potassium. It is suggested that specialized literature be consulted before preparing admixtures with aminophylline and other drugs.</p><p>&nbsp;</p><p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not administer unless solution is clear and container is undamaged. Discard unused portion. Do not use if crystals have separated from solution.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Shelf life: 18 months
Do not use Aminophylline after the expiry date which is stated on the abel after EXP:. The expiry date refers to the last day of that month.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25&deg;C</p><p>Protect from light. Store in carton until time of use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aminophylline Injection, USP 25 mg/mL is supplied in single-dose containers</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>SINGLE-DOSE CONTAINER. Discard unused portion.</p><p>&nbsp;</p><p>Keep out of the sight and reach of children.</p><p>&nbsp;</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER

Hospira, Inc., Lake Forest, IL 60045 USA

MANUFACUTRED BY

Hospira INC, Rocky Mount, United states.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                March 2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>